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Nucleoside Modifications Suppress RNA Activation of Cytoplasmic RNA Sensors
Abstract
Multiple innate defense pathways exist to recognize and defend against foreign nucleic acids. Unlike
innate immune receptors that recognize structures specific for pathogens that are not shared by
mammalian hosts — for example, toll-like receptor (TLR)4-lipopolysaccharide, TLR5-flagellin, NOD1 and
2-peptidoglycan — all nucleic acids are made from four components that are identical from bacteria to
man. Nucleoside modifications are prevalent in nature but vary greatly in their distribution and frequency,
and therefore could serve as patterns for recognition of pathogenic nucleic acids. The presence of
modified nucleosides in RNA reduces the activation of RNA-sensing TLRs and retinoic acid inducible gene
I (RIG-I), which initiate signaling cascades following activation and result in transcription of proinflammatory genes. Unexpectedly, translation of in vitro transcribed mRNA is enhanced by incorporation
of modified nucleosides, but the mechanism responsible for this enhanced translation has not been
identified. To identify the pathways responsible for enhanced translation of modified nucleosidecontaining mRNA, we studied two cytoplasmic RNA-sensing innate defense mechanisms known to
influence translation, the RNA-dependent protein kinase (PKR) pathway and the 2-5A system
(oligoadenylate synthetase [OAS] and RNase L). Using purified protein in vitro, cell culture, and in vivo
mouse studies, we show that unmodified in vitro transcribed mRNA activates PKR and OAS and is rapidly
cleaved by RNase L. However, we show that incorporation of modified nucleosides into in vitro
transcribed mRNA reduces each of these pathways. Furthermore, we demonstrate that these pathways
are necessary for enhanced translation of mRNA containing modified nucleosides. Additionally, we
demonstrate that the presence of pseudouridine in in vitro transcripts increases mRNA half-life following
delivery. From these data, we conclude that unmodified in vitro transcribed mRNA is stimulatory to the
cytoplasmic RNA sensors PKR and OAS. This stimulation is reduced by the presence of modified
nucleosides. The enhanced translation of mRNA containing modified nucleosides results from reduced
PKR and OAS activation. These data support a larger interpretation that the absence or reduction in
frequency of modified nucleosides in RNA is a common pattern for recognition of pathogenic RNA by
numerous innate defense systems.
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ABSTRACT

NUCLEOSIDE MODIFICATIONS SUPPRESS RNA ACTIVATION OF
CYTOPLASMIC RNA SENSORS

Bart R. Anderson
Dissertation Supervisor: Drew Weissman, M.D., Ph.D.

Multiple innate defense pathways exist to recognize and defend against foreign nucleic
acids. Unlike innate immune receptors that recognize structures specific for pathogens
that are not shared by mammalian hosts — for example, toll-like receptor (TLR)4lipopolysaccharide, TLR5-flagellin, NOD1 and 2-peptidoglycan — all nucleic acids are
made from four components that are identical from bacteria to man. Nucleoside
modifications are prevalent in nature but vary greatly in their distribution and frequency,
and therefore could serve as patterns for recognition of pathogenic nucleic acids. The
presence of modified nucleosides in RNA reduces the activation of RNA-sensing TLRs
and retinoic acid inducible gene I (RIG-I), which initiate signaling cascades following
activation and result in transcription of pro-inflammatory genes. Unexpectedly,
translation of in vitro transcribed mRNA is enhanced by incorporation of modified
nucleosides, but the mechanism responsible for this enhanced translation has not been
identified. To identify the pathways responsible for enhanced translation of modified
nucleoside-containing mRNA, we studied two cytoplasmic RNA-sensing innate defense
vi

mechanisms known to influence translation, the RNA-dependent protein kinase (PKR)
pathway and the 2-5A system (oligoadenylate synthetase [OAS] and RNase L). Using
purified protein in vitro, cell culture, and in vivo mouse studies, we show that unmodified
in vitro transcribed mRNA activates PKR and OAS and is rapidly cleaved by RNase L.
However, we show that incorporation of modified nucleosides into in vitro transcribed
mRNA reduces each of these pathways. Furthermore, we demonstrate that these
pathways are necessary for enhanced translation of mRNA containing modified
nucleosides. Additionally, we demonstrate that the presence of pseudouridine in in vitro
transcripts increases mRNA half-life following delivery. From these data, we conclude
that unmodified in vitro transcribed mRNA is stimulatory to the cytoplasmic RNA
sensors PKR and OAS. This stimulation is reduced by the presence of modified
nucleosides. The enhanced translation of mRNA containing modified nucleosides results
from reduced PKR and OAS activation. These data support a larger interpretation that the
absence or reduction in frequency of modified nucleosides in RNA is a common pattern
for recognition of pathogenic RNA by numerous innate defense systems.

vii

Table of Contents

Dedication ........................................................................................................................iii
Acknowledgements..........................................................................................................iv
Abstract ............................................................................................................................vi
Table of Contents.............................................................................................................viii
List of Figures ..................................................................................................................xii
CHAPTER 1
Introduction....................................................................................................................1
1.1 Innate nucleic acid sensing ..................................................................................1
1.2 RNA modification................................................................................................2
1.3 Influence of modified nucleosides on RNA immunogenicity .............................7
1.4 Influence of modified nucleosides in RNA on pro-inflammatory
RNA receptors .....................................................................................................11
1.5 Influence of modified nucleosides on RNA sensors PKR and OAS ...................14
1.6 Additional RNA sensors for which the influence of modified
nucleosides has not been tested............................................................................15
1.7 Translation of mRNA containing modified nucleosides .....................................17
1.8 Nuclease resistance of RNA containing modified nucleosides ...........................19
1.9 Aims and organization of dissertation .................................................................20
CHAPTER 2
Incorporation of pseudouridine into mRNA enhances translation by
diminishing PKR activation .......................................................................................23
viii

2.1 Introduction..........................................................................................................24
2.2 Materials and methods .........................................................................................26
2.3 Results..................................................................................................................32
Conventional in vitro transcribed mRNA induces translational repression
Conventional in vitro transcribed mRNA activates PKR
Pseudouridine-containing mRNA does not activate PKR in cells
Translation of unmodified mRNA is enhanced upon inhibiting
or eliminating PKR
Pseudouridine-containing mRNA is not bound by PKR
2.4 Discussion ............................................................................................................44
CHAPTER 3
Nucleoside modifications in RNA reduce OAS activation and ability
to be cleaved by RNase L............................................................................................50
3.1 Introduction..........................................................................................................51
3.2 Materials and methods .........................................................................................53
3.3 Results..................................................................................................................58
mRNA containing nucleoside modifications activates OAS less
than unmodified mRNA
Pseudouridine-containing mRNA induces less rRNA cleavage
than unmodified mRNA
RNase L cleaves uridine-containing RNA more readily than Ψ-containing RNA
RNase L facilitates enhanced translation of Ψ-containing mRNA in cells
and after in vivo administration
ix

Pseudouridine-containing mRNA is actively translated longer
than unmodified mRNA
Nucleoside-modified mRNA has an increased half-life
3.4 Discussion ............................................................................................................68
CHAPTER 4
Nucleofection induces eIF2α
α phosphorylation mediated by GCN2 and PERK.......73
4.1 Introduction..........................................................................................................74
4.2 Materials and methods .........................................................................................76
4.3 Results..................................................................................................................78
Nucleofection induces eIF2α phosphorylation in WT MEF cells
Lipid and polymer transfection reagents do not induce eIF2α
phosphorylation in WT MEF cells
GCN2−/− delays and reduces nucleofection-induced eIF2α phosphorylation
GCN2 and PERK are responsible for nucleofection-induced
eIF2α phosphorylation
4.4 Discussion ............................................................................................................85
CHAPTER 5
Conclusions, implications, and future directions ........................................................89
5.1 Summary of results ..............................................................................................89
5.2 RNA danger recognition ......................................................................................89
5.3 Roles of modified nucleosides in pathophysiology .............................................91
5.4 Implications for therapeutic RNA delivery..........................................................93
5.5 Future directions and applications .......................................................................95
x

APPENDIX A
Induction of HIV-specific T and B cell responses with a replicating and
conditionally infectious lentiviral vaccine.................................................................98
A.1 Abstract ...............................................................................................................99
A.2 Introduction.........................................................................................................100
A.3 Materials and methods ........................................................................................103
A.4 Results.................................................................................................................109
Lentiviral transduction of murine DC
Formation of viral cores in transduced cells
“Second-round” transduction of DC
T and B cell responses to vaccination
A.5 Discussion ...........................................................................................................123
References........................................................................................................................130

xi

List of Figures
CHAPTER 1
Figure 1-1. Structures of uridine and pseudouridine and base-pairing to adenosine.......4
Figure 1-2. Incorporation of modified nucleosides into mRNA during
in vitro transcription....................................................................................8
Figure 1-3. Cytokine production by RNA transfected DCs.............................................9
Figure 1-4. Activation of DCs by RNA ...........................................................................10
Figure 1-5. In vitro translation of nucleoside-modified mRNAs.....................................18
CHAPTER 2
Figure 2-1. Translational inhibition by unmodified in vitro transcribed mRNA.............33
Figure 2-2. Activation of purified PKR by in vitro transcribed RNA .............................35
Figure 2-3. PKR activation in cells by in vitro transcribed mRNA.................................38
Figure 2-4. Translation of in vitro transcribed mRNA in the absence of PKR activity ..40
Figure 2-5. mRNA containing modified nucleosides does not inhibit PKR activation...42
Figure 2-6. Ψ-containing mRNA does not pull down PKR ............................................43
Figure 2-7. Double-stranded characteristics of mRNA ...................................................46
CHAPTER 3
Figure 3-1. OAS activation by mRNA containing modified nucleosides .......................59
Figure 3-2. Induction of rRNA cleavage by in vitro transcribed mRNA ........................61
Figure 3-3. Cleavage of Ψ-containing RNA by RNase L................................................62
Figure 3-4. Translation of unmodified and Ψ-containing mRNA in wild-type and
RNase L−/− cells and mice.............................................................................64
Figure 3-5. Translation of Ψ-containing mRNA in cell culture ......................................65
Figure 3-6. Half-life of Ψ-containing mRNA..................................................................67
CHAPTER 4
Figure 4-1. Phosphorylation of eIF2α in wild-type cells following nucleofection .........79
Figure 4-2. Phosphorylation of eIF2α in wild-type cells following transfection ............80
Figure 4-3. Phosphorylation of eIF2α in kinase-deficient cells
following nucleofection ................................................................................82
Figure 4-4. Phosphorylation of eIF2α in dual-knockout cells
following nucleofection ................................................................................84
APPENDIX A
Figure A-1. Map of the VRX418 and VRX494 lentiviral vector genomes .....................110
Figure A-2. eGFP and p24 gag protein expression in transduced DC.............................111
Figure A-3. Extracellular p24 gag production by transduced DC ...................................113
Figure A-4. EM of bone marrow-derived DC transduced with VRX418........................116
Figure A-5. Second-round transduction...........................................................................118
Figure A-6. T cell responses to vaccination with VRX418-transduced DC....................120
Figure A-7. Antibody responses to VRX418-transduced DC vaccination ......................122
Figure A-8. Illustration of mechanism for second-round transduction............................125
xii

CHAPTER 1

Introduction

1.1 Innate nucleic acid sensing
Human cells contain extensive systems to recognize the presence of pathogens
and cell damage as signs of danger to the cell or tissue and to limit their spread. Innate
recognition of these dangers relies on pattern recognition of danger-associated molecular
patterns (DAMPs) by host defense proteins known as pattern-recognition receptors (PRR).
All pathogens contain nucleic acids encoding their genome and nucleic acids are released
during necrotic cell death 52, therefore exogenous nucleic acids are associated with
pathogenicity and can serve as DAMPs.
Numerous nucleic acid-sensing PRR exist, and the presence of additional
receptors, which have not yet been characterized, is indicated by nucleic-acid signaling
that occurs independently of known pathways 240. All of these receptors must perform the
task of identifying nucleic acids associated with danger, which must be distinguished
from normal cellular DNA and RNA. As has been proposed, protein-coating of cellular
nucleic acids and compartmentalization of PRR away from cellular nucleic acid ligands
likely contribute to differential recognition of danger-associated nucleic acids 53, but do
not fully account for nucleic-acid DAMP identification. Molecular features of the nucleic
acids themselves are also important determinants. For example, long, perfectly doublestranded (ds)RNA is produced during replication of some viruses, but is not otherwise
present in substantial amounts in cells and activates several PRR 30. Other examples for
1

molecular determinants of nucleic acid recognition include the presence of 5’triphosphate on cytoplasmic RNA 115 and unmethylated cytidine in CpG motifs of DNA
112

. Other distinguishing features of danger-associated nucleic acids remain unidentified.
The immunogenicity of RNA is well established, having been demonstrated using

multiple approaches 13, 129, 140, 184, 207. One surrogate measure of RNA immunogenicity is
cytokine release by dendritic cells (DC) following exogenous delivery of RNA. This
approach has been used to compare the immunogenicity of RNA from various sources. It
was demonstrated that bacterial RNA is immunostimulatory, but less so if only the tRNA
fraction is delivered. Mammalian RNA is much less immunostimulatory, and again with
variable potency depending on the RNA fraction tested. Mitochondrial RNA, which is
very similar to bacterial RNA, was responsible for the majority of immunostimulation by
mammalian RNA. In contrast to mammalian mRNA, in vitro transcribed mRNA is highly
immunostimulatory 130. There is an inverse relationship between the immunogenicity of
these RNA fractions and the frequency of nucleoside modifications they contain, which
suggests nucleoside modification as a determinant of RNA immunogenicity 132.

1.2 RNA modification
Although fundamentally consisting of four nucleosides – adenosine (A), cytidine
(C), guanosine (G), and uridine (U) – RNA in nature is rife with variations. In addition to
damage-induced modifications, there are over 100 different nucleoside modifications that
are formed in RNA during normal maturation 212. These modifications are found in all
domains of life, although the number and types of modification vary greatly between

2

species 173. In general, both the types of modifications found and the number of modified
nucleosides present increase when moving up the evolutionary ladder 42.
The most common modification, both in terms of frequency and species
distribution, is pseudouridine (Ψ; also known as 5-ribosyluridine), which has been found
in nearly all species studied to date. Pseudouridine is formed by isomerization of uridine.
The N1−C1’ glycosyl linkage between uracil and ribose is broken, uracil is rotated 180º
around its N3−C6 axis, and is then reattached with a C5−C1’ uracil-ribose linkage (Figure
1-1). This confirmation leaves the imino nitrogen on pseudouridine free to form an
additional hydrogen bond that is not present in uridine, which contributes to its unique
properties. The presence of pseudouridine in RNA facilitates base-stacking interactions,
increases rigidity in both single-stranded (ss) and double-stranded (ds)RNA, and
stabilizes RNA secondary structures. Importantly, base-pairing between pseudouridine
and adenosine remains intact 43.

3

Figure 1-1. Structures of uridine and pseudouridine and base-pairing to adenosine
In pseudouridine, uracil is linked to ribose via C5 instead of the N1 linkage found in
uridine (C5 and N1 are indicated in bold type). Hydrogen bonds between adenosine and
uridine or pseudouridine are indicated by dotted lines. Additional hydrogen bonding
potential of pseudouridine is indicated by dashed arrow.

Another common modification is the addition of a methyl group, including 2’-Omethylation of ribose (Nm) and base methylation, such as N 6-methyladenosine (m6A), 5methylcytidine (m5C), and 5-methyluridine (m5U; also known as ribothymidine). Other
modifications include addition of thiol groups, such as 2-thiouridine (s2U), hydroxyl
groups, amino acids derivatives, and others, as well as combinations of modifications on
the same nucleoside 212.
Maturation-associated RNA modifications are formed post-transcriptionally in a
site-specific manner, either through the use of specific enzymes or by enzymes directed
4

by guide RNAs 273. In eukaryotic organisms, RNA modification occurs primarily in the
nucleus, and therefore mitochondrial RNA (mtRNA) contains the fewest modified
nucleosides of any mammalian RNA fraction 157. By far, the most heavily modified
fraction of cellular RNA is tRNA, where in mammals up to 25% of the nucleosides
contain modification 157. Modifications are also common in rRNA, which accounts for
~80% of RNA in cells, with approximately 250 RNA modification sites occurring in
human rRNA 145. Multiple methylation variants occur for a uniquely 5’−5’ triphosphatelinked N 7-methylguanosine (m7G) cap that is found on RNAs transcribed by RNA
polymerase II, including mRNA, snRNA, and pri-miRNA 27. Internal modification of
mRNA is primarily m6A, averaging 3–5 m6A per mRNA, although m6A is absent in some
mRNAs. Additionally, there have been limited reports of m5C in mRNA 27, 179. RNA
modifications are also found in most other fractions of cellular RNA including snRNA,
snoRNA, and miRNA.
The function of modified nucleosides in RNA is poorly understood. In many
cases blocking RNA modifications produces no obvious impact in vitro, leaving the
question of their biological roles unresolved 145. However, the importance of RNA
modification is demonstrated by the evolutionary conservation of both RNA modification
in general as well as specific modification sites. Furthermore, genes encoding RNAmodifying enzymes are essential, as demonstrated in yeast 145. RNA modification is best
studied in tRNA, where RNA modifications have been shown to have roles in stabilizing
critical tRNA structures and in fine-tuning decoding in translation 97. Highly
thermophillic organisms have increased tRNA modifications, adding support for their
role in stabilizing RNA structures. Modified nucleosides in rRNA have also been closely
5

examined, where a limited number of specific modifications are required for maximal
translation 145, 255. In the absence of data showing specific roles for other modification
sites, it has been suggested that their role is to stabilize rRNA structure 145. The m7G cap
found on mRNA facilitates nuclear export, protects the RNA from exonuclease attack,
and has a well-established role in enhancing the translation of mRNA through capbinding proteins 27. The major naturally-occurring internal nucleoside modification in
mRNA is m6A. Inhibition of m6A methylation does not change RNA stability 35, and
instead is thought to play a role in pre-mRNA splicing and transport 27, although this is
disputed by a recent study of m6A in unspliced yeast mRNA 26.
In addition to the naturally-occurring nucleoside modifications discussed above, a
plethora of chemically synthesized modifications and nucleoside analogs have been
developed. Nucleoside analogs are used as investigational and FDA-approved antiviral
and chemotherapeutic agents 79. Chemically-synthesized modified nucleosides have been
incorporated into nucleic acids, often with the intent to increase nuclease resistance 45.
While beneficial in proper circumstances, these modified nucleosides also present the
dangers of re-entering the cellular NTP pool where they may interfere with RNA or DNA
synthesis 146, 148. In contrast, it has been demonstrated that naturally-occurring modified
nucleosides do not re-enter the NTP pool, and cellular pathways exist for their controlled
removal 24. A goal of the laboratory is to develop modified RNA for therapeutic use,
including transient gene therapy and vaccination. For this reason, only nucleoside
modifications that occur naturally during RNA maturation will be examined and
discussed in this dissertation.

6

1.3 Influence of modified nucleosides on RNA immunogenicity
Following the observation that high levels of nucleoside modification correlate
with low RNA immunostimulation, the affect that the presence of modified nucleosides
have on RNA immunogenicity was tested by measuring immunostimulation of DC by in
vitro transcribed RNA. The immunogenicity of in vitro transcribed mRNA is evidenced
by cytokine release from DC following mRNA transfection. To generate in vitro
transcribed RNA, one or more NTPs were replaced with a corresponding modified NTP
in phage polymerase transcription reactions. This led to the complete replacement of one
nucleoside with a modified nucleoside (Figure 1-2). mRNA containing modified
nucleosides stimulated less cytokine production by DC. In monocyte-derived DC
(MDDC), this impact was observed for RNA containing m5C, m6A, Ψ, and s2U. In
primary DC, only U modifications — Ψ, s2U, and m5U — reduced RNA immunogenicity,
whereas m6A and m5C did not (Figure 1-3). Similarly, modified nucleosides reduced the
RNA-induced activation of MDDC, as measured by upregulation of maturation marker
CD83 on the cell surface (Figure 1-4) 130.

7

Figure 1-2. Incorporation of modified nucleosides into mRNA during in vitro
transcription
Aliquots (1 µg) of in vitro-transcribed RNA-1571 without (none) or with m5C, m6A, Ψ,
m5U, or s2U nucleoside modifications were analyzed on denaturing agarose gel followed
by ethidium bromide-staining and UV illumination. Reprinted with adaptations from
Immunity, 23(2), Katalin Karikó, Michael Buckstein, Houping Ni, and Drew Weissman,
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside
Modification and the Evolutionary Origin of RNA, 165–175, Copyright 2005, with
permission from Elsevier.

8

Figure 1-3. Cytokine production by RNA transfected DCs
MDDC (A and C), IFN-α MDDCs (B), and primary DC1 and DC2 (D) were treated for
8–16 hr with lipofectin alone or complexed with R-848 (1 µg/ml) or the indicated RNA
(5 µg/ml). Modified nucleosides present in RNA-1571 are noted. TNF-α, IL-12(p70),
and IFN-α were measured in the supernatant by ELISA. Mean values ± SEM are shown.
The results are representative of ten (A and C), four (B), and six (D) independent
experiments. N.D., not determined. Reprinted with adaptations from Immunity, 23(2),
Katalin Karikó, Michael Buckstein, Houping Ni, and Drew Weissman, Suppression of
RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and
the Evolutionary Origin of RNA, 165–175, Copyright 2005, with permission from
Elsevier.
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Figure 1-4. Activation of DCs by RNA
MDDCs were treated for 20 hr with lipofectin alone or complexed with R-848 (1 µg/ml)
or the indicated RNA (5 µg/ml). Modified nucleosides present in RNA-1571 are
indicated. (A) CD83 and HLA-DR staining is shown. (B) TNF-α was measured in the
supernatants by ELISA (the asterisk represents cells that were cultured in 30-fold larger
than usual volume of medium for flow cytometry). Mean fluorescence of CD80 and
CD86 was determined by flow cytometry. Data are representative of four independent
experiments. Reprinted with adaptations from Immunity, 23(2), Katalin Karikó, Michael
Buckstein, Houping Ni, and Drew Weissman, Suppression of RNA Recognition by Tolllike Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of
RNA, 165–175, Copyright 2005, with permission from Elsevier.

Studies in other systems also observed reduced immunostimulation by RNA
containing modified nucleosides. The reduced immunogenicity of RNA containing m5C
was confirmed in peripheral blood mononuclear cells (PBMC) 236. The dsRNA
polyinosinic:polycytidylic acid (poly(I:C)) is a well established immunostimulatory RNA.
However, the presence of 2’-O-methylated inosine (I) or C in poly(I:C) reduces the
stimulation of type I interferon (IFN) production by primary human fibroblasts 95.
Subsequently, multiple studies found that 2’-O-methylation (Nm) reduces RNA
immunostimulation of human PBMC, which has become a popular strategy for reducing
the immunogenicity of siRNAs 123, 171, 231.

1.4 Influence of modified nucleosides in RNA on pro-inflammatory RNA receptors
The observation that incorporation of modified nucleosides reduced RNA
immunogenicity promoted interest in understanding how modified nucleosides influence
activation of RNA receptors that initiate pro-inflammatory signaling pathways. The tolllike receptor (TLR) family of receptors contains 10 members in humans, which respond
to diverse stimuli 135. Three endosomally-located TLRs respond to RNA: TLR3, 7, and 8.
11

TLR3 is activated by dsRNA 1. Both TLR7 and TLR8 are activated by ssRNA in humans
66, 111, 130

, although the agonists of TLR8 are less well characterized, in part because its

functional relevance in mice is debated 124, 156. It has been reported that poly-U RNA
activates TLR7 66, 67, 111, but this has not been replicated in all studies 130. Activation of
TLRs initiates nuclear factor-κB (NF-κB) and interferon regulatory factor (IRF) signaling
pathways, resulting in production of pro-inflammatory cytokines 195. Additionally,
closely related TLR9 is stimulated by unmethylated DNA, but not by DNA containing 5methyl-deoxycytidine in CpG motifs 112, establishing a precedent that nucleoside
modification can alter TLR activation. Activation of individual TLRs by in vitro
transcribed RNA was tested in stably transformed 293T cell lines, each transfected with a
single RNA-responsive TLR. Unmodified in vitro transcribed RNA was stimulatory to all
three RNA-responsive TLRs. However, RNA containing modified nucleosides m5C, Ψ,
m6A, m5U, or s2U did not stimulate TLR7 and TLR8. In cells expressing TLR3, m5Ucontaining RNA was as stimulatory as unmodified RNA, and the presence of Ψ or m5C
only modestly decreased stimulation. In contrast, incorporation of m6A or s2U into RNA
eliminated stimulation of TLR3-transformed cells 130. In another report, Am also reduced
TLR7-mediated IFN production in plasmacytoid DC 219.
The cytoplasmic RIG-I-like receptor (RLR) family was discovered more recently,
consisting of retinoic acid inducible gene-I (RIG-I), melanoma differentiation-associated
gene 5 (MDA5), and laboratory of genetics and physiology-2 (LPG-2). The archetype of
the family, RIG-I, is best studied and is thought to be activated by RNA containing 5’triphosphates (5’ppp) 115, although ongoing debate continues 253. It has also been
suggested that the uridine content of RNA plays an important role in RIG-I activation 215.
12

MDA5 is thought to be activated by longer dsRNA or branched RNA molecules 196, 270.
The role of LPG-2 is much less clear, but because it lacks a key protein-interacting
domain, it has been proposed to serve in regulatory roles 210, 218, 256, 270. In human
monocytes and plasmacytoid DC, 5’ppp-bearing RNA stimulated IFN-α production, but
not if the RNA contained Ψ, s2U, or Um, suggesting that RIG-I is not activated by RNA
containing modified U 115. For Ψ, this was later confirmed through comparison of IFN
induction in wild-type (WT) and RIG-I−/− murine embryonic fibroblast (MEF) cell lines
131

. Subsequently, it was demonstrated that RIG-I binds RNA containing Ψ but is not

activated, and therefore Ψ-modified RNA functions as a competitive inhibitor of RIG-I
activation 253. Additionally, the modified nucleoside inosine (I) can be formed by the
deamination of adenosine, and cytoplasmic dsRNA containing I:U base pairs inhibits
IRF3 activation, suggesting that IU-dsRNA inhibits RLR activation 258. No studies
directly examining the influence of modified nucleosides on MDA5 or LPG-2 have been
reported.
Activation of RNA signaling receptors promotes increases in both innate and
adaptive immune responses 29. The combined data examining TLR and RLR indicate a
trend toward reduced activation of RNA signaling receptors by RNA that contains
modified nucleosides. Furthermore, there are indications that modification of uridine may
be especially significant and, therefore, additional studies of U-modifications are
warranted.
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1.5 Influence of modified nucleosides on RNA sensors PKR and OAS
In addition to RNA receptors that initiate signaling cascades leading to new
transcription of pro-inflammatory proteins, there exist RNA sensing pathways that result
in more immediate effector functions without requiring new transcription. The best
characterized of these effector-type RNA sensors are RNA-activated protein kinase
(PKR) and oligoadenylate synthetase (OAS).
PKR was classically characterized as an anti-viral protein that is activated by
binding to long, perfectly double-stranded RNA. Binding to dsRNA allows activation of
PKR by dimerization and autophosphorylation. The primary substrate of activated PKR is
the alpha subunit of eukaryotic translation initiation factor 2 (eIF2α). Phosphorylation of
eIF2α reduces functional translation initiation complexes and, therefore, globally inhibits
translation in an affected cell 88. In addition to long, perfect dsRNA, subsequent studies
have demonstrated activation of PKR by numerous RNA ligands, provided that they
contain some feature with RNA secondary structure 18, 21, 57, 121, 188, 244, 280. Studies using
poly(I:C) demonstrated that the presence of Im or Cm in dsRNA reduced PKR activation
247

. When PKR was activated by short RNAs containing modified nucleosides, the effects

were different in ssRNA than in dsRNA. PKR activation by short ssRNA required 5’ppp
and the presence of nucleoside modifications eliminated PKR activation. In comparison,
PKR activation by short dsRNA was much higher and was increased if RNA contained
m5U or m6A, reduced by the incorporation of Ψ, and eliminated by the presence of s2U or
s4U 177.
OAS is not a single protein, but instead represents a small family of 8−10 related
proteins arising from gene duplication and alternative splicing. Similar to PKR, OAS was
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originally characterized as an anti-viral protein activated by long dsRNA, but additional
RNA activators have since been identified 63, 109, 167-169, 225. Upon activation, OAS uses
ATP to form unique, small 2’−5’ linked oligoadenylate molecules, which are collectively
called 2-5A. These 2-5A in turn activate a latent cytoplasmic endoribonuclease named
RNase L. Activated RNase L cleaves ssRNA with limited specificity, including exposed
loops on rRNA, cellular RNA, and exogenous RNAs, such as pathogenic or transfected
RNAs 23. Activation of OAS by poly(I:C) is reduced by the presence of Im or Cm 247.
Effects of other nucleoside modifications on activation of OAS have not been reported.

1.6 Additional RNA sensors for which the influence of modified nucleosides has not
been tested
Multiple additional innate RNA-sensing pathways exist upon which the influence
of modified nucleosides have not been studied. Only a brief overview of these pathways
will be presented here.
General control non-derepressible-2 (GCN2) is closely related to PKR, and
similarly functions to inhibit translation through phosphorylation of eIF2α. Activation of
GCN2 can be induced by a wide variety of cell stresses, including nutrient deprivation
and certain viral RNAs. Regardless of the initiating stress, GCN2 activation is thought to
function through sensing of uncharged tRNAs. The mechanism by which GCN2
recognizes uncharged tRNAs is not well understood 64. Because tRNA contains more
modified nucleosides than any other RNA fraction, it would be interesting to study how
modified nucleosides affect activation of GCN2.
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In addition to TLR and RLR, a third family of signaling receptors that result in
pro-inflammatory cytokine production are the nucleotide-binding domain (NBD)– and
leucine-rich-region (LRR)–containing receptors (NLRs). Among these, it was recently
demonstrated that in addition to other ligands, viral and ssRNA activate nucleotidebinding oligomerization domain 2 (Nod2), resulting in IFN production 214. Similarly,
bacterial RNA was discovered as an activating ligand for NACHT, leucine rich repeat
and PYD containing 3 (Nalp3) 128.
RNA-specific adenosine deaminase (ADAR) converts adenosine to inosine in
dsRNA. This can be an anti-viral response, permitting RNA cleavage by I-RNase.
However, RNA editing by ADAR also has important cellular functions 248. Similarly, the
apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) family are
RNA editing proteins which deaminate C to U in RNA and DNA in response to various
cellular and viral stimuli 201.
It was recently discovered that leucine-rich repeat flightless-interacting protein 1
(LRRFIP1) is activated by both dsRNA and dsDNA, resulting in IFN-β production
through IRF3. This activity allows LRRFIP1 to contribute to IFN-β production by
macrophages in response to vesicular stomatitis virus (VSV) and the intracellular
bacterial pathogen Listeria monocytogenes 269.
The high-mobility group box (HMGB) proteins have also been demonstrated to
possess RNA- and DNA-binding characteristics. Rather than directly initiating a
signaling pathway themselves, it is proposed that they facilitate activation of other RNA
receptors, including TLR and possibly RLR 268.
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1.7 Translation of mRNA containing modified nucleosides
With the exception of 5’-cap methylation, the most commonly found modification
in mRNA is m6A 27, although there have been limited reports of mRNAs containing m5C
72, 73, 234

and a unique mRNA that contains Ψ 278. Modified nucleosides can be

experimentally incorporated into mRNA during in vitro transcription, and this approach
has been used to study how translation is influenced by modified nucleosides in mRNA.
In cell culture, no translation of the transfected mRNA occurred if mRNA contained
complete replacement of U with s2U or of A with m6A, although if mRNA contained 5%
m6A, which is similar to the naturally-occurring rate, translation was equivalent to
unmodified mRNA. In contrast, translation was enhanced if mRNA contained Ψ or m5C.
Enhanced translation of Ψ-containing RNA was also observed following RNA delivery
to mice. When translation of Ψ-containing mRNA was examined in lysate systems,
enhanced translation was observed in rabbit reticulocyte lysate, but translation was
reduced in wheat-germ extract and eliminated in E. coli lysate (Figure 1-5) 131. These data
suggest that the mechanism for enhanced translation of Ψ-containing mRNA requires
factors found in higher eukaryotes but absent in plants and prokaryotes.
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Figure 1-5. In vitro translation of nucleoside-modified mRNAs
Rabbit reticulocyte lysate, wheat germ extract, and Escherichia coli S30 lysate were
incubated in the presence of 50 ng/µl mRNA encoding firefly luciferase (TEVlucA50) or
Renilla luciferase (capRen). The mRNAs contained the indicated nucleoside
modifications. Fold increase in translation was calculated by normalizing the measured
relative light units to those obtained with non-modified mRNA. Error bars indicate SEM
(n = 4), and the dotted line represents the relative value obtained with unmodified mRNA
in each of the lysates. Adapted by permission from Macmillan Publishers Ltd: Molecular
Therapy 2008 Nov;16(11):1833-40, copyright 2008.

The direct influence of U-modifications on the translation apparatus has been
examined by assessing scanning-dependent translation initiation and elongation in rabbit
reticulocyte lysates. The presence of Ψ reduced the efficiency of both initiation complex
formation and processive translation elongation. Initiation was reduced by m5U, but
elongation was unaffected. The presence of s4U, in contrast, substantially increased
initiation but was not permissive for elongation. Additionally, s4U was permissive for
leaky scanning and initiation, while Ψ was not 7.
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The only RNA modification tested in both studies was Ψ, which despite being
used less efficiency by the translational apparatus resulted in enhanced net translation of
the encoded reporter protein. These data therefore suggest that RNA containing Ψ has
additional effects on translation that do not result from direct impacts on the translational
apparatus.

1.8 Nuclease resistance of RNA containing modified nucleosides
In the human genome, hundreds of genes encode products involved in nuclease
digestion of RNA. Evolutionary studies suggest that the eight vertebrate-specific RNases
may have evolved from a host-defense RNase 235. Indeed, numerous RNases have
primary or secondary defense functions, including I-RNase, RNase L, RNases 1−8, and
dicer. Together, these facts point to evolutionary pressure to control exogenous RNA as a
self-defense mechanism. Additionally, multiple pathways exist for degradation of mRNA,
which is important to control the quality, quantity, and timing of gene expression 16.
Altered endonuclease cleavage has been reported for RNA containing nucleoside
modifications. RNA containing Nm are more stable in serum 15, suggesting that they are
resistant to cleavage by serum nucleases, which are predominantly A-type RNases 235.
Although pancreatic diesterase and snake venom phosphodiesterase do cleave Ψcontaining RNA, there is some indication that they may do so with reduced efficiency 180.
However, the presence of Ψ has not been shown to prevent cleavage by the nucleases
RNase A, RNase H 279, RNase T1, RNase T2, or nuclease P1. RNA containing Um is not
bound or cleaved by RNase L 250.
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1.9 Aims and organization of dissertation
In this dissertation, I seek to identify how nucleoside modifications alter the
activity of RNA sensors and effectors, specifically PKR, OAS, and RNase L. These
studies will further our understanding of the specificity of recognition and activity of
these receptors/enzymes and the mechanisms used by the host to identify pathogenic
RNA and differentiate it from self RNA. In doing so, these studies will also contribute to
a deeper understanding of how nucleoside modifications alter the translation and stability
of exogenously delivered in vitro transcribed mRNA. The primary hypothesis of this
dissertation is that nucleoside modifications inhibit activation of intracellular RNA
sensors PKR and OAS and the effector function of RNase L. A secondary
hypothesis is that modification of RNA can be employed to reduce immune
activation and increase the translation and stability of exogenously delivered mRNA.
The results of experiments testing these hypotheses are presented in three chapters.
Each experimentation chapter contains the individually relevant background, detailed
methods, results, and conclusions. Following the results chapters, the final chapter of this
dissertation will discuss the overall conclusions and implications of this dissertation, as
well as future directions and applications of this work.
The first results chapter, Chapter 2, focuses on PKR. Nucleoside modifications
have been shown to influence the translation of in vitro transcribed mRNA and also the
activation of RNA sensors, including TLR and RLR. Therefore, we postulated that
nucleoside modifications influence translation through PKR, a RNA sensor that inhibits
translation following activation. We hypothesized that unmodified in vitro transcribed
mRNA activates PKR, resulting in global inhibition of translation, but that mRNA
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containing modified nucleosides does not activate PKR, and therefore translation
continues uninhibited. We tested the in vitro activation of purified PKR by mRNA, as
well as examining PKR and eIF2α phosphorylation induced in cell culture following
mRNA transfection. Translation of modified and unmodified mRNA was assessed in the
absence of PKR activity using PKR inhibitors and PKR−/− MEF cells. In vitro PKR
activation and immunoprecipitation from cell lysates were used to investigate the
mechanism by which modified RNA influences PKR activation. The results of these
experiments have been published 3, and the information contained in Chapter 2 is an
adaptation of that publication.
Chapter 3 presents experiments addressing OAS and RNase L, which comprise
the protein components of the 2-5A system. Activation of the 2-5A system can influence
both translation and stability of RNA. Because both OAS and RNase L are RNA
interacting proteins, nucleoside modifications in RNA could influence the 2-5A system in
multiple ways. We hypothesized that unmodified in vitro transcribed mRNA activates
OAS and is cleaved by activated RNase L, but that nucleoside modifications in RNA
reduce OAS activation and RNase L mediated RNA cleavage. Purified proteins were
used for in vitro assays to examine OAS activation by mRNA and mRNA cleavage by
RNase L. Using northern blotting, the half-life of mRNA was assessed following
incubation in RRL, transfection in cell culture, and injection into mice. Luciferase
enzyme activity and northern blots were used to assess translation and retention of
reporter mRNA in RNase L−/− MEF cell culture and RNase L−/− mice. The degradation of
rRNA following mRNA transfection was evaluated to address the mechanism by which
the 2-5A system affects translation following exogenous delivery of mRNA. Chapter 3 is
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based upon a manuscript that has been prepared for publication and will be submitted for
publication following review by all co-authors.
The experiments in Chapter 4 study the impact of nucleofection on translation.
Although commonly used, lipid-based transfection reagents vary in effectiveness
depending on cell type and can be toxic to cells. Nucleofection is a popular and effective
alternative delivery method based on electroporation using cell type-specific buffers and
electrical parameters. While using nucleofection for mRNA delivery, we observed that
nucleofection induced phosphorylation of eIF2α. Using western blotting, we examined
nucleofection-induced eIF2α phosphorylation in cells deficient for individual eIF2α
kinases PKR, general control non-derepressible 2 (GCN2), and PKR-like endoplasmic
reticulum kinase (PERK). The impact of other transfection reagents on eIF2α
phosphorylation is also presented.
Prior to investigating the influence of modified nucleosides on cytoplasmic RNA
sensors, I performed studies on a conditionally-replicating RNA vaccine strategy based
on transduction of dendritic cells with a lentiviral vector. Because these experiments are
outside of the scope of this dissertation, they will not be discussed further in the body of
this dissertation. This work was published 263 and is included herein as Appendix A.
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CHAPTER 2

Incorporation of pseudouridine into mRNA enhances translation by diminishing
PKR activation

Originally published in Nucleic Acids Research (2010) 38(17): 5884-5892.
doi:10.1093/nar/gkq347. Reprinted with adaptations by permission of Oxford University
Press.
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2.1 Introduction
In vitro transcribed mRNA has many advantages as a vehicle for gene delivery.
Transfection of mRNA is very efficient 262 and rapid expression of the encoded protein
can be achieved. In addition, unlike viral vectors or plasmid DNA, cell-delivered mRNA
does not introduce the risk of insertional mutagenesis 70, 185. Previous studies have shown
that mRNA can activate a number of innate immune receptors, including TLR3, TLR7,
TLR8, and RIG-I. However, activation of these receptors can be avoided by
incorporating modified nucleosides, e.g., Ψ, s2U, and others into the RNA 115, 130.
PKR is a ubiquitous mammalian enzyme with a variety of cellular functions,
including regulation of translation during conditions of cell stress. During viral infection,
PKR binds viral dsRNA, autophosphorylates, and subsequently phosphorylates eIF2α,
thus repressing translation 77, 120. Originally, potent activation of PKR was thought to
require >30 base pair-long dsRNA 167. It has subsequently been shown that PKR can be
activated by a variety of RNA structures that include ssRNA containing hairpins
structures 21, 121, imperfect dsRNA containing mismatches 21, short dsRNA with singlestranded tails 280, stem-loop structures with 5’-triphosphates 56, 178, and unique elements
present in interferon gamma and TNF-alpha mRNAs 125. Viral 76, 225 and cellular RNAs 18,
57, 188, 244

transcribed as single-stranded RNA but containing secondary structure can also

be potent PKR activators. PKR activation by short dsRNA, such as siRNA, has also been
demonstrated 5, 93, 203, 222, 232, 277. These reports indicate that a wide variety of RNA
structures can activate PKR, provided they contain some dsRNA element. Modified
nucleosides present in homopolymeric RNAs 49, 166, 246, 247 or in short transcripts 177, 202,
203

can influence activation of PKR. However, it has not been investigated whether
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modified nucleosides present in long, protein-encoding mRNAs impact activation of
PKR.
Previously, we demonstrated that in vitro transcribed mRNAs containing Ψ and
m5C are translated at significantly higher levels than those containing unmodified
nucleosides 131. However, the molecular mechanism underlying this enhancement has not
been identified. Here, we show that one cause of this translational difference is that Ψ
and m5C-containing mRNA activates PKR less efficiently than uridine-containing mRNA.
This reduced PKR activation also mitigates general translational inhibition of cellular
proteins that is induced when unmodified in vitro transcribed mRNAs are delivered to
cells.

25

2.2 Materials and methods
Cells and reagents
Human embryonic kidney (HEK) 293T cells were obtained from the American
Type Culture Collection and were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 2 mM L-glutamine (Life Technologies), 100 U/mL
penicillin and 100 µg/mL streptomycin (Invitrogen), and 10% fetal calf serum (HyClone).
Immortalized wild-type (WT) and PKR knockout (PKR–/–) mouse embryonic fibroblasts
(MEFs) were generously provided by Robert Silverman (Cleveland Clinic Foundation)
and were maintained in RPMI medium supplemented with 2 mM L-glutamine, 100 U/mL
penicillin, 100 µg/mL streptomycin, and 10% fetal calf serum. Polyinosinic:polycytidylic
acid (poly(I:C)), yeast tRNA, and human poly(A)+ RNA were purchased from Sigma and
polydeoxycytidylic acid (poly(dC)) was purchased from Midland Certified Reagent Co.

mRNA synthesis
Reporter plasmids encoding firefly luciferase (pT7TS-fLuc and pTEVluc) or
Renilla luciferase (pT7TS-Ren) were linearized with SalI/BamHI to generate templates.
Transcriptions were performed at 37°C for 3 hours using T7 RNA polymerase and
nucleotide triphosphates at 7.5 mmol/l final concentration (MEGAscript kit; Ambion).
Except where otherwise specified, capped mRNA was generated by performing
transcription in the presence of 6 mmol/L cap analog 3’-O-Me-m7G(5’)ppp(5’)G (New
England Biolabs) and lowering the concentration of guanosine triphosphate (3.75
mmol/l). All mRNAs were transcribed to contain 30 or 50 nt-long 3’ poly(A) tails.
Selected mRNAs were further poly(A)-tailed in a reaction of ~1.5 µg/µl RNA, 5 mmol/l
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adenosine triphosphate, and 60 U/µl yeast poly(A) polymerase (USB) and incubated at
30°C for 3 hours according to the manufacturer’s instructions. The length of poly(A) tails
were estimated to be ~200-nt long and is indicated with An. Triphosphate-derivatives of
Ψ, s2U, m5C, m6A, and m5U (TriLink) were used in place of their cognate unmodified
NTP to generate modified nucleoside-containing RNA. Following transcription, the
template plasmids were digested with Turbo DNase and RNAs were precipitated with 2.5
M lithium chloride at –20°C for 4 h. RNAs were pelleted by centrifugation, washed with
75% ethanol and then reconstituted in nuclease-free water. The concentration of RNA
was determined by measuring the optical density at 260 nm. All RNA samples were
analyzed by denaturing agarose gel electrophoresis for quality assurance. Each RNA type
was synthesized in 4–10 independently performed transcription experiments and all
experiments were performed with at least two different batches of mRNA. Enzymatic
capping was performed using ScriptCap m7G capping kit (Epicentre) on mRNA
transcribed with guanosine 5'-[γ-32P]-triphosphate (GE Healthcare). Efficiency of capping
was verified by monitoring the elimination of γ-32P from the mRNA. Biotinylated mRNA
was transcribed with the addition of 1:5 biotinylated CTP (Roche Applied Sciences) in
the transcription reaction.

Detection of reporter proteins in RNA-transfected cells
Cells were seeded into 96-well plates at a density of 5.0 × 104 cells/well one day
prior to transfection. RNA was complexed with lipofectin (Invitrogen) according to the
method of 130, as follows. Potassium phosphate buffer was prepared and supplemented 1
µg/µl bovine serum albumin (BSA; Sigma). RNA was diluted in cold serum-free DMEM
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to 0.07 µg/µl. Stock phosphate buffer was added to give final concentrations of 20 mM
potassium phosphate, pH 6.4, and 100 ng/ml BSA. For 3 wells, lipofectin complexed
RNA was prepared in the following ratios: 2.4 µl (2.4 µg) was added to 21.3 µl diluted
phosphate buffer, and then incubated at room temperature for 10 minutes. Then 9.9 µl
nucleic acid (0.69 µg) was added and the mixture was incubated for 10 additional
minutes at room temperature. Lastly, 116.4 µl serum-free DMEM was added to bring up
the final volume to 150 µl. The mixture was vortexed and 48 µl of it (0.25 µg RNA/well)
was added directly cells plated in 96-well plates. Transfected cells were incubated for 1 h
at 37ºC in a 5% CO2 incubator. The lipofectin-RNA mixture was removed and replaced
with 200 µl pre-warmed DMEM containing 10% FCS, and cells were further cultured at
37ºC until lysis. Cells were lysed in 25 µl firefly, Renilla, or dual-luciferase specific lysis
reagents (Promega). Aliquots of 2 µl were assayed with the corresponding enzyme
substrates and a LUMAT LB 950 luminometer (Berthold) at a 10-second measuring time.

Assessment of total protein synthesis
HEK293T cells were seeded into 96-well plates at a density of 5.0 × 104 cells/well
with 1000 U/mL interferon-αA/D (Sigma) one day prior to transfection. Cells were
incubated in methionine/cysteine-free medium (Invitrogen) for 1 hour, then pulsed with
complete medium supplemented with 35S-methionine/cysteine (140 mCi/mL)
(PerkinElmer) for 1–3 hours. Cells were lysed in RIPA lysis buffer supplemented with
protease inhibitor cocktail (Sigma). Lysate was diluted in 0.1% BSA, and
macromolecules were precipitated by the addition of trichloroacetic acid (TCA) and 30
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minutes incubation on ice. Precipitates were filtered onto glass microfiber filters
(Whatman) and washed with 10% TCA and 100% ethanol. Incorporated 35Smethionine/cysteine was quantified using Ecolite(+) scintillation cocktail (MP
Biomedicals) and a Beckman LS 6000IC scintillation counter.

PKR activation in vitro
Recombinant human PKR containing a (His)6 tag 280 was expressed in E. coli
strain BL21(DE3) grown in LB media. PKR was purified from E. coli lysate by passing
lysate over a Ni-NTA-agarose FPLC column. Immediately prior to use, purified PKR was
dephosphorylated by incubating 5.33 µM PKR with 1280 units lambda protein
phosphatase (New England Biolabs) for 60 minutes at 30ºC, then stopping phosphatase
activity by the addition of 1 mM sodium orthovanadate (MP Biomedicals). Final
concentrations of 0.75 µM dephosphorylated PKR, 0.1 mM ATP, and 0.15 µCi/µL
adenosine 5'-[γ-32P]-triphosphate (γ-32P-ATP) (PerkinElmer) were mixed with the
indicated concentration of RNA for 10 minutes at 30°C in a buffer consisting of 4 mM
MgCl2, 100 mM KCl, and 20 mM HEPES, pH 7.5. The reaction was stopped by the
addition of NuPage LDS sample buffer and reducing agent (Invitrogen) and heating for
10 minutes at 70°C. Unincorporated γ-32P-ATP was separated from radiolabeled PKR by
running samples on a 12% SDS-PAGE gel. Phosphorylated PKR was imaged in dried
gels using a phosphor storage screen (Molecular Dynamics) and detected using Storm or
Typhoon Phosphorimagers (GE Healthcare). Band densities were quantified using
ImageQuant software (GE Healthcare).

29

Western blotting
HEK293T cells were seeded into 96-well plates at a density of 5.0 × 104 cells/well,
with 1000 U/mL interferon-αA/D one day prior to transfection. At the indicated time
following RNA transfection, cells were lysed in RIPA lysis buffer supplemented with
protease inhibitor cocktail and HALT phosphatase inhibitor (Pierce). Equal mass of
protein (10−30 µg per sample) was loaded onto a 12% SDS-PAGE gel. Proteins were
subsequently transferred to a Hybond-P PVDF membrane (GE Amersham), blocked with
2.5% non-fat milk in TBS containing 0.05% Tween 20, and probed with antibodies for
PKR-pT446 and PKR (Epitomics), eIF2α-pS51 and eIF2α (Cell Signaling Technologies),
or PABP (Abcam). Membranes were stripped by agitating gently in a buffer of 2% SDS,
100 mM β-mercaptoethanol, 62.5 mM Tris pH 6.7 for 30 minutes at 50°C, then
subsequently re-blocked and re-probed. Image was captured using the Fujifilm LAS1000
digital imaging system. Linear brightness and contrast were adjusted using GIMP 2.6
software.

Biotinylated RNA pull down
HEK293T cells were seeded into 96-well plates at a density of 5.0 × 104 cells/well one
day prior to transfection. Where indicated, cells were incubated in methionine/cysteinefree medium (Invitrogen) for 30 minutes, then pulsed with complete medium
supplemented with 35S-methionine/cysteine (140 mCi/mL) (PerkinElmer) for 3.5 hours
prior to lysis. HEK293T cells were lysed in RIPA lysis buffer supplemented with
protease inhibitor cocktail and RNase inhibitor (RNasin, Promega). Biotinylated mRNA
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(0.5−2 µg) was added to 25 µL lysate and incubated on ice for 2 hours. Subsequently, 50
µL of streptavidin-agarose bead 50% slurry (Invitrogen) was added and incubated on ice
for 1 hour. Beads with bound RNA and proteins were centrifuged and washed, and
proteins were released from RNA by heating samples at 70°C for 10 minutes in the
presence of NuPage LDS sample buffer and reducing agent. Samples were separated by
10% SDS-PAGE and transferred to PVDF membranes. PKR and poly(A)-binding protein
(PABP) were detected by western blotting.

Statistical analysis
All data are reported as mean ± standard error of the mean (SEM). Statistical
differences between treatment groups were calculated by the Student’s t-test using
Microsoft Excel. For all statistical testing, a P-value <0.05 was considered significant.
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2.3 Results
Conventional in vitro transcribed mRNA induces translational repression
We previously observed that mRNA transcribed in vitro containing Ψ in place of
uridine or m5C in place of cytidine is translated more efficiently than mRNA containing
unmodified nucleosides 131. In order to determine whether the translational enhancement
exerted by Ψ incorporated into RNA is restricted to the modified transcript or also
extends to unmodified transcripts, we performed co-transfection experiments delivering
equal amounts of Renilla and firefly luciferase-encoding mRNAs to cells. As expected,
the mRNAs were translated much more efficiently when both contained Ψ as compared
to when both were unmodified (Figure 2-1A). However, when only one of the mRNAs
contained Ψ modification, the translation level of the Ψ-containing RNA decreased
(~50%) relative to the level measured when both contained Ψ. One explanation for these
findings could be that unmodified RNA inhibits the translation of the co-delivered RNA,
while Ψ-containing RNA has no such inhibitory effect. To explore whether translation of
endogenous cellular mRNAs are similarly influenced by exogenously delivered in vitro
transcribed mRNAs, total cellular protein synthesis was monitored in cells transfected
with mRNA containing Ψ modification or no modification. Both types of mRNA reduced
cellular protein translation; however, the suppression of protein synthesis was greater
with unmodified RNA than with Ψ-containing RNA (Figure 2-1B). PKR-activating
poly(I:C) and non-activating poly(dC) were used as controls. Mock transfected cells were
treated with the transfection reagent (lipofectin) only, without nucleic acid.
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Figure 2-1. Translational inhibition by unmodified in vitro transcribed mRNA
(A) In vitro transcribed mRNAs encoding Renilla luciferase (Ren) and firefly luciferase
(Luc) were synthesized with and without Ψ modifications then mixed (1:1 mass ratio) as
indicated. The mixed mRNA was complexed with lipofectin and added to HEK293T
cells seeded in 96-well plates (0.25 µg RNA/well). Cells were lysed 4 h after transfection
and dual luciferase measurements were performed in aliquots (1/20th) of the lysates.
Values presented are normalized to cells transfected with Ren and Luc mRNAs when
both contained Ψ modifications. Error bars indicate the standard error of n = 3 samples.
(B) Unmodified or Ψ-containing RNA was complexed with lipofectin and delivered to
HEK293T cells. Cells were subsequently incubated with 35S-methionine/cysteine
supplemented medium, lysed, and proteins were TCA precipitated. Data are presented as
percentage of counts obtained from mock transfected cells. Data shown are mean values
from three independent experiments ± SEM.

Conventional in vitro transcribed mRNA activates PKR
To determine whether the inhibition of translation by unmodified mRNA is
mediated by PKR, in vitro transcribed mRNAs were first analyzed in a cell-free system
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using purified PKR. Four different mRNAs were tested: unmodified and Ψ-modified
mRNA, each with either a cap or a triphosphate at their 5’ end (5’ppp). In vitro
transcribed mRNA with 5’ppp and containing uridines activated PKR to a greater extent
than those containing Ψ (Figure 2-2A). Neither UTP nor ΨTP alone activated PKR
(Figure 2-2B). This reduced activation of PKR by Ψ-containing transcripts is consistent
with the previously observed enhancement of in vitro translation from Ψ-containing RNA
in rabbit reticulocyte lysates 131. Since the presence of 5’ppp on short RNAs has
previously been shown to enhance the activation of PKR 56, 178, it was important to
determine whether the 5’ppp present on long mRNAs also contributed to PKR activation.
To remove 5’ppp, in vitro transcripts were capped enzymatically (Figure 2-2C), which
completely removed the 5’ppp, and then tested. As Figure 2-2A demonstrates, the
presence or absence of 5’ppp on unmodified and Ψ-modified transcripts did not
significantly alter their ability to activate PKR. It has been shown that a variety of
nucleoside modifications in RNA can influence the activation of RNA sensors 115, 130, 177;
therefore, the effect of incorporating the modified nucleosides s2U, m5C, m6A, or m5U
into mRNA was also analyzed. The mRNA containing s2U, m5C, or m6A activated PKR
to a lesser extent than unmodified RNA, while RNA with m5U activated PKR to the
greatest extent (Figure 2-2D and E). For comparison, PKR activation by natural RNAs
was also tested. Like in vitro transcribed mRNA, natural mRNA activated PKR, and this
activation was higher than PKR activation induced by Ψ-containing in vitro transcribed
mRNA. In contrast, natural tRNA did not activate PKR (Figure 2-2F).
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Figure 2-2. Activation of purified PKR by in vitro transcribed RNA
Purified PKR was incubated with γ-32P-ATP and in vitro transcribed mRNA for 10 min.
Reaction products were separated by SDS-PAGE and imaged using phosphor storage
radiography. (A) Unmodified or Ψ-containing mRNAs encoding firefly luciferase
contained triphosphates (ppp) or cap at their 5’ ends were analyzed. Complete capping of
RNA was achieved post-transcriptionally using vaccinia capping enzyme. Concentration
of mRNA in reactions was 3.1, 6.2, 12.5, and 25 µg/mL. No RNA (−) and 79 bp dsRNA
were used as negative and positive controls. Quantified phosphorylation is presented as a
bar graph above each band. Values were normalized to those obtained with 25 µg/mL
uncapped, unmodified RNA. (B) Purified PKR was mixed with γ-32P-ATP and the
indicated nucleotide triphosphates at 200, 20, 2, and 0.2 nM concentrations. Reaction
products were separated by SDS-PAGE and imaged using phosphor storage radiography.
No RNA and 200bp dsRNA were used as negative and positive controls, respectively.
(C) RNA transcribed in the presence of γ-32P-GTP was capped enzymatically, separated
on a denaturing agarose gel, stained with ethidium bromide and UV illuminated. RNA
was then transferred to a nylon membrane and exposed to film. (D) Purified PKR was
mixed with γ-32P-ATP and in vitro transcribed firefly luciferase mRNA that contained the
indicated modified nucleosides. Reaction products were separated by SDS-PAGE and
imaged using phosphor storage radiography. A representative of three independent
experiments is shown. (E) Quantification of PKR activation by mRNA containing
modified nucleosides. Data represented as mean value ± SEM from five independent
experiments using 5–25 ng/µL RNA, normalized to PKR activation by unmodified RNA.
Asterisks indicate P-values <0.05 calculated by two-tailed Student’s t-test. (F) Purified
PKR was activated using 125 µg/mL yeast tRNA, 25 µg/mL Ψ-containing in vitro
transcribed mRNA, or 25 µg/mL human poly(A)+ RNA. Poly(dC) and 200 bp dsRNA
(ds) were used as negative and positive controls. Quantified phosphorylation is presented
as a bar graph above each band.

Pseudouridine-containing mRNA does not activate PKR in cells
Next, we investigated the impact of Ψ-containing mRNA on PKR activation in
the complex cellular environment. Following control studies demonstrating that RNAs
with or without nucleoside modification can be delivered to cells with the same
efficiency (data not shown), unmodified or Ψ-containing mRNA was complexed with
lipofectin and delivered into HEK293T cells. PKR activation was assessed by western
blot using an antibody specific for PKR phosphorylated on Thr446, a site at which
phosphorylation is requisite for PKR activation 209. Consistent with the results observed
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using purified PKR, transfection of unmodified transcript induced PKR phosphorylation,
which was dramatically reduced if the transfected RNA contained Ψ (Figure 2-3A).
Similarly, incorporation of s2U or m5C into RNA reduced the level of PKR
phosphorylation relative to that induced by unmodified RNA, while m5U incorporation
into RNA enhanced PKR phosphorylation (Figure 2-3B). Incorporation of m6A into RNA
also enhanced PKR phosphorylation in cells, despite reducing PKR activation in vitro.
Phosphorylation of eIF2α, a substrate of PKR, was induced in HEK293T cells by
transfection with unmodified RNA but not with Ψ-containing RNA (Figure 2-3C).
Incorporation of modified nucleosides other than Ψ into mRNA altered the
phosphorylation of eIF2α in direct parallel to their alterations of PKR phosphorylation
(Figure 2-3D). To exclude the possibility that ΨTP either free or complexed with
lipofectin induced PKR or eIF2α phosphorylation, cells were treated with UTP or ΨTP
and western blotted. Neither UTP nor ΨTP induced PKR or eIF2α phosphorylation in
cells (Figure 2-3E).
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Figure 2-3. PKR activation in cells by in vitro transcribed mRNA
In vitro transcribed firefly luciferase mRNA incorporating the indicated modified
nucleoside (A−D) or UTP and ΨTP (E) were complexed with lipofectin and delivered to
HEK293T cells. Following cell lysis at 4 hours after transfection, proteins were separated
by SDS-PAGE, and phosphorylation of PKR (A, B and E) and eIF2α (C, D and E) was
assessed by western blotting. No RNA (−), poly(dC), and poly(I:C) were used as controls.
Relative phosphorylation is indicated below each gel lane, calculated as phosphorylated
band density divided by total band density and then normalized to the phosphorylation
induced by unmodified RNA. Arrowhead in (D) indicates the eIF2α band below a
heavier non-specific band and arrowhead in (E) indicates the phospho-eIF2α band above
a heavier non-specific band. Representative images of at least three independent
experiments are shown.

Translation of unmodified mRNA is enhanced upon inhibiting or eliminating PKR
Viral proteins C8L of swinepox and K3L of vaccinia are inhibitors of PKR and
have been shown to reverse PKR-mediated inhibition of translation in mammalian cells
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133

. Thus, to confirm the role of PKR in the translational differences observed between

uridine- and Ψ-containing transcripts, we utilized C8L, K3L, and two K3L mutants:
hyperactive K3L-H47R and inactive K3L-Y76A 133, 134. Based on the premise that PKR is
activated by in vitro transcribed mRNAs that contain uridine but not by those with Ψ,
inhibition of PKR would be expected to increase the translation of unmodified mRNA
but have no effect on the translation of Ψ-containing RNA. Indeed, in the presence of
PKR inhibitors, the amount of translation increased from unmodified transcripts but not
from Ψ-modified transcripts (Figure 2-4A).
Further evidence confirming the role of PKR in suppressing translation of
unmodified mRNAs was obtained using mouse embryonic fibroblasts (MEFs) derived
from PKR-knockout animals. In wild-type MEFs, translation of Ψ-containing transcripts
was 4−5-fold greater than that of unmodified transcripts (Figure 2-4B). In PKR-deficient
MEFs, the amount of translation of Ψ-modified mRNA was not different from that of
unmodified mRNA. Notably, the equivalent translation of unmodified and Ψ-containing
mRNA was not due to reduced translation of Ψ-modified mRNA. In fact, when
comparing raw RLU data, the translation of both unmodified and Ψ-containing mRNAs
increased in PKR−/− cells relative to WT cells; however, the increase in translation of
unmodified mRNA was disproportionately larger than the increase in translation of Ψmodified mRNA (Figure 2-4C). Additionally, RNA transfection does not induce
phosphorylation of eIF2α in PKR-deficient MEFs, as it does in WT cells (Figure 2-4D).
These results demonstrate that the activity of PKR is necessary for the decreased
translation of unmodified transcripts relative to Ψ-containing transcripts.
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Figure 2-4. Translation of in vitro transcribed mRNA in the absence of PKR activity
(A) HEK293T cells were transfected with plasmids encoding protein inhibitors of PKR:
swinepox C8L protein, wt vaccinia K3L, hyperactive K3L-H47R, inactive K3L-Y76A, or
pG5 empty vector. Twenty-four hours later, unmodified or Ψ-modified in vitro
transcribed mRNAs encoding firefly luciferase were complexed with lipofectin and
delivered to cells and luciferase activity was measured 4 hours later. Data were
normalized to values obtained when cells were first transfected with empty vector then
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with unmodified RNA. Presented data are mean values from three replicates ± SEM. (B
and C) MEF cell lines derived from wild-type (WT) or transgenic mice that do not
express functional PKR (PKR−/−) were transfected with unmodified or Ψ-containing in
vitro transcribed mRNAs encoding firefly luciferase. Data were normalized to values
obtained when cells were transfected with unmodified RNA and expressed as fold
increase in translation of Ψ-containing mRNA over unmodified RNA (B) or displayed
without normalization (C). Values are from three replicate wells ± SEM and are
representative of at least three independently performed experiments. (D) WT and PKR–/–
MEF cells were transfected with unmodified or Ψ-containing in vitro transcribed mRNAs
encoding firefly luciferase or mock transfected with no RNA (–). Cells were lysed 2
hours following RNA transfection; proteins were then separated by SDS-PAGE and
assayed for eIF2α phosphorylation by western blotting. Relative phosphorylation is
indicated above each gel lane, calculated as phosphorylated band density divided by total
band density and then normalized to the phosphorylation induced by unmodified RNA in
wild-type cells. Absence of PKR was also confirmed by western blotting.

Pseudouridine-containing mRNA is not bound by PKR
To test whether Ψ-modified mRNA is a competitive inhibitor of PKR, a 200 bp
dsRNA known to activate PKR was mixed with a 5−125-fold mass excess of Ψ-modified
RNA. All concentrations of Ψ-modified RNA tested failed to inhibit the activation of
PKR by the 200 bp dsRNA (Figure 2-5A). Similarly, a 125-fold mass excess of mRNA
containing s2U, m5C, or m6A did not inhibit PKR activation by dsRNA (Figure 2-5B).
The results were the same using lower mass excess, equal mass, or equal molar mixes
(data not shown), demonstrating that RNAs containing modified nucleosides are not
competitive inhibitors of PKR. The lack of PKR inhibition by transcripts containing
modified nucleosides suggests a lack of binding between PKR and modified RNAs. To
directly test this, biotinylated transcripts having 30 nt-long poly(A) tails and containing
either Ψ or uridine were mixed with HEK293T cell lysates and complexes were then
precipitated using streptavidin-agarose beads. Unmodified mRNA pulled down
substantially more total protein than Ψ–modified mRNA, including multiple bands that
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bound to unmodified mRNA but not to Ψ-containing mRNA (Figure 2-6A). Western
blots of the precipitates indicated that PKR bound to unmodified, but bound poorly to Ψmodified RNA (Figure 2-6B), consistent with reduced activation of PKR by Ψcontaining RNA. By contrast, equal amounts of PABP were pulled down by both RNAs.
These results indicate that unmodified RNA, but not Ψ-modified RNA, is bound by PKR.

Figure 2-5. mRNA containing modified nucleosides does not inhibit PKR activation
An activating 200 bp dsRNA was mixed with a 5–125-fold mass excess of in vitro
transcribed firefly luciferase mRNA containing Ψ (A) or a 125-fold mass excess of
mRNA containing the indicated modified nucleoside (B) prior to incubation with purified
PKR. Reaction products were separated by SDS-PAGE. Relative band densities are
presented below each gel lane and normalized to dsRNA only. Data shown are
representative of three independent experiments.
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Figure 2-6. Ψ-containing mRNA does not pull down PKR
Biotinylated in vitro transcribed unmodified or Ψ-containing RNAs were incubated with
HEK293T cell lysates for 2 hours. The RNA and bound proteins were pulled down using
streptavidin-agarose beads. An aliquot of lysate that was incubated only with beads but
without RNA (−) was also processed. Aliquots of pull down proteins as well as the
supernatants were separated by SDS-PAGE. (A) HEK293T cells were pulsed with 35Smethionine/cysteine for 4 hours prior to lysis. Following pull down and gel separation,
35
S was visualized by radiofluorography. Diamonds indicate bands specifically pulleddown by unmodified RNA. Star indicates band specifically pulled down by Ψ-modified
RNA. (B) Pull down of PKR and PABP was detected by western blotting. Relative band
densities of PKR divided by PABP compared to unmodified RNA are presented below
each gel lane.
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2.4 Discussion
We demonstrate that modified nucleosides in mRNA reduce PKR activation and
identify a mechanism by which nucleoside modification in mRNA enhances translation
of the encoded protein. Our data show that conventional in vitro transcribed RNA inhibits
translation of reporter and cellular mRNAs, in part through the activation of PKR.
However, this inhibitory activity is not induced by Ψ or m5C-containing mRNA. Using
multiple lines of investigation, our studies demonstrate that unmodified in vitro
transcribed mRNA activates PKR, resulting in phosphorylation of eIF2α and inhibition
of translation. Replacement of 5’ppp with 5’cap structure on the mRNA does not
substantially alter this PKR activation. Examining translation in the context of PKR
inhibitors and in PKR-deficient cells confirmed that enhanced translation of Ψ-containing
mRNA is a consequence of diminished PKR activation. Mechanistically, modified
nucleoside incorporation reduces RNA recognition by PKR. This is supported by data
demonstrating that RNAs containing modified nucleosides do not inhibit PKR activation
by dsRNA and that PKR binds poorly to Ψ-containing RNA.
PKR activation by unmodified RNA has a more pronounced impact on translation
of the transfected reporter mRNA than on total cellular translation (Figure 2-1). A similar
local translation effect has been observed with PKR activation by IFN-γ mRNA 18, 48. The
pronounced local inhibition is likely due to the kinetics of phosphorylation and
dephosphorylation of PKR. Activated PKR most dramatically inhibits local translation
because rapid dephosphorylation of PKR limits the impact on more distant translation.
Therefore, translation of a PKR-activating mRNA is more severely impacted than total
cellular translation. Furthermore, the observation that Ψ-containing RNA also causes
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some reduction in total protein synthesis suggests that there are additional effects on
cellular translation, which are not mediated by PKR.
Ψ-containing RNA activates PKR more effectively in vitro as compared to in vivo
(Figs. 2-2 and 2-3). One possible reason for this difference is that PKR activation in vivo
occurs in the presence of competing factors such as phosphatases, components of the
translational system and other proteins affecting the structure and accessibility of the
RNA to PKR. In contrast, in vitro assays lack such competing factors that would limit or
reverse PKR phosphorylation.
Although mRNA is normally transcribed without a complementary antisense
transcript or long stretches of self-complementarity, it contains many short doublestranded regions and other intramolecular secondary structures (Figure 2-7). In addition
to long perfectly double-stranded RNA, PKR is activated by RNA that contains either
hairpins 121, bulges, mismatched base-pairing 21, short internal dsRNA regions 280, or
unique structures naturally present in selected cellular mRNAs 18, 57, 188, 244. As previously
demonstrated for TLR3 132, it is likely that the activation of PKR by in vitro transcribed
mRNA is due to the formation of intra- and intermolecular secondary structures. PKR is
then activated upon binding to these structures, similar to the classical dsRNA-mediated
mechanism of PKR activation. Nucleoside modifications influence base pairing and
secondary structure formation 43, 136, 144, 155, 176, 239, 282, 283, which likely contribute to their
effects on PKR activation. Alterations to the shape of the helix formed and interruptions
to the minor groove, which is presumed to be the principal location of PKR interaction
with RNA 20, 177, 213, are also likely to play significant roles in determining how each
modified nucleoside will impact RNA-mediated PKR activation.
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Figure 2-7. Double-stranded characteristics of mRNA
mFold web server prediction of firefly and Renilla luciferase mRNA secondary structures.
Unlike short ssRNAs 178, PKR activation by long in vitro transcribed mRNA is
not dependent on the presence of a 5’-triphosphate, as mRNA containing complete
replacement of 5’ppp with cap structure also activates PKR (Figure 2-2A and C). The
difference between these findings might reflect the amount of 5’ppp in the RNAs being
compared. Forty-seven nt-long ssRNA induced 100-fold more PKR activation when the
5’-end contained triphosphates 178, while our data did not show any significant effect of
removing the 5’ppp from 1976 nt-long mRNA, which contains ∼40-fold less 5’ppp. Our
finding is more consistent with the result reported for 47 bp-long dsRNA, wherein PKR
activation did not depend on 5’ppp 178.
Previous reports indicate that PKR activation is altered by the presence of
modified nucleosides in homopolymeric RNA 166, 246, 247 and short ssRNA and dsRNA 177.
Our data extends these findings by demonstrating that incorporation of modified
nucleosides into long in vitro transcribed mRNA also alters activation of PKR and
subsequent translation of the RNA. We observe substantial PKR activation by in vitro
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transcribed mRNA, which is reduced by incorporation of Ψ. Additionally, our studies
show reduced PKR activation by mRNA that contains m5C, enhanced PKR activation by
mRNA containing m5U, and elimination of PKR activation by s2U-containing mRNAs.
These results vary from those obtained when testing PKR activation by short 47 nt
ssRNA: a low level of PKR activation by unmodified RNA, which was dependent on the
presence of a 5’-triphosphate, and near complete elimination of PKR activation by
incorporation of modified nucleosides 177. However, when testing short 47 bp dsRNA, the
effects observed were similar to those reported here: PKR activation by unmodified RNA,
which is reduced by Ψ incorporation, increased by m5U incorporation, and eliminated by
s2U incorporation. This similarity to short dsRNA, and dissimilarity to ssRNA, supports
our model that PKR activation by long in vitro transcribed mRNA, where 5’ppp is
limited, is due to regions of secondary structure formed within the RNA.
Unlike the other nucleoside modifications tested, the presence of m6A in mRNA
impacted PKR activation differently in vivo compared to in vitro. In vitro, mRNA
containing m6A activated PKR only moderately (Figure 2-2D and E) whereas in vivo,
m6A-containing mRNA activated PKR more potently than unmodified RNA (Figure 23B). Although the significance of this observation is not fully understood, the
discrepancy may be explained by the presence of additional factors in cells that facilitate
increased double-stranded formation in m6A-containing mRNA in vivo.
Nucleic acids containing modified nucleosides can act as antagonists of nucleic
acid-sensing TLRs 103, 208, 260, 272. Therefore, we asked whether mRNAs containing
modified nucleosides inhibit activation of PKR by its cognate ligand, dsRNA. PKR is
still activated by dsRNA in the presence of a 125-fold excess of mRNA containing Ψ or
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other modified nucleosides (s2U, m5C, or m6A), indicating that mRNAs containing
modified nucleosides are not inhibitors of PKR (Figure 2-5). This extends previous data
demonstrating that short ssRNAs containing modified nucleosides do not inhibit PKR 177.
Furthermore, in cell lysates, RNA containing Ψ pulls down less PKR than RNA
containing uridine (Figure 2-6B). This reduction in PKR binding is consistent with prior
in vitro data demonstrating small reductions in PKR binding to short dsRNA and ssRNA
that contain modified nucleosides 177. From these data, we conclude that the mechanism
of reduced PKR activation is reduced recognition and binding to RNA containing
modified nucleosides.
It is possible that mRNAs with different nucleoside modifications have different
optimal concentration for activating PKR. Figures 2-2 and 2-3 indicate that none of the
modified nucleosides tested, with the exception of s2U, completely eliminate PKR
activation. Rather, each modified nucleoside might alter the ability of RNA to bind and
activate PKR (Figure 2-6B).
PKR plays an integral part in the cellular response to viral RNA. However,
mechanisms to avoid PKR activation by cellular RNAs are required, as constitutive PKR
activation and translational inhibition would obstruct normal cellular function. Here, our
data show that PKR activation is reduced when RNAs contain nucleoside modifications
that are naturally present in many cellular RNAs, including piRNA 138, snRNA, tRNA,
mRNA, and rRNA 212. Activation of TLRs 130 and RIG-I 115 is also influenced by
modified nucleosides in RNA and most commonly RNA modifications decrease the
immunogenicity of RNA. Together, these data support a general interpretation that
modified nucleosides supply a pattern for differential recognition by RNA binding
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proteins. One purpose of common natural modifications may be avoiding activation of
PKR and other RNA sensors by self RNA.
Using mRNA for gene delivery has the benefits of efficient transfection and rapid
protein expression without the risk of insertional mutagenesis. The potential of mRNA as
a delivery vehicle is enhanced further by incorporating modified nucleosides that reduce
host defense responses initiated by PKR, TLRs, and RIG-I 115, 130, 177. We observed the
additional benefit of increased translation from Ψ and m5C-containing mRNA 131. In vitro
transcribed mRNA is regularly delivered to cells in a research setting and has entered
clinical trials as a cancer vaccine. As the interest in non-coding RNA continues, the
delivery of RNA is likely to continue expanding. In most cases, activating PKR is an
unwanted side-effect. High translation and low immunogenicity make mRNA containing
Ψ or m5C applicable to express therapeutic proteins, whereas s2U-modified RNA is best
suited for applications where avoiding non-specific immunogenicity is desirable but
where translation is unnecessary 131, such as delivering antisense RNA 200 or stimulating
RNA interference.
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CHAPTER 3

Nucleoside modifications in RNA reduce OAS activation
and ability to be cleaved by RNase L
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3.1 Introduction
The antiviral 2-5A system is initiated when double-stranded (ds)RNA is bound by
2'-5'-oligoadenylate synthetases (OAS), of which 8−10 isoforms exist due to gene
duplication and alternative splicing. These isoforms have divergent cellular localization 44,
are differentially induced by IFNs 117, produce different size 2-5A molecules 117, and each
possess unique activation parameters and catalytic profiles 160. However, the specific
roles for each OAS variant are not well understood. In addition to 2-5A production, the
alternatively spliced 9-2 isozyme of OAS1 can act as a pro-apoptotic mediator
independent of 2-5A production 90. Recently extracellular OAS1 was demonstrated to
have antiviral activity independent of 2-5A production 142. OAS2 binds to NOD2, which
enhances its antiviral effects and suggests an involvement with antibacterial defenses as
well 74.
OAS proteins lack any homology to known RNA-binding motifs and instead rely
on a positively charged groove for RNA binding 108. In addition to dsRNA, OAS can be
activated by specific viral RNAs 63, 169, 225, 226, ssRNA aptamers 109, and even certain
cellular mRNAs 168. A recent report indicated that interaction with the minor groove of
the consensus sequence NNWWNNNNNNNNNWGN is required for OAS1 activation
by short dsRNA 139.
Activated OAS links ATP into unique, short 2’−5’-linked oligomers called 2-5A
[px5'A(2'p5'A)n; x = 1–3; n ≥ 2]. The primary function of 2-5A is activation of the latent
endoribonuclease RNase L. Binding of RNase L monomers by 2-5A allows RNase L
dimerization and exposes the nuclease domain. Activated RNase L cleaves ssRNA
preferentially following UU or UA dinucleotides (reviewed in 229).
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Certain OAS proteins produce distinct profiles of 2-5A sizes. For instance, OAS3
predominantly produces 2-5A dimers, which do not activate RNase L 206. Therefore, it
has been proposed that 2-5A might also have other cellular functions. Consistent with this
proposal, a recent report indicated that in addition to RNase L activation, 2-5A4 also
serves as a TLR4 ligand 68.
The 2-5A system is a conserved host defense pathway, with evidence of the 2-5A
system found down to marine sponges, the lowest metazoa 223. In response, pathogens
have evolved strategies to circumvent the 2-5A system, such as inhibition of OAS
activation by HSV1 Us11 protein 216 and inhibition of RNase L activity by a conserved
structure in poliovirus RNA 104.
Here, we report that the presence of modified nucleosides in RNA has multiple
effects on the 2-5A pathway. Unmodified in vitro transcribed mRNA activates OAS,
resulting in rRNA cleavage and reduced translation. Additionally, unmodified mRNA is
more rapidly cleaved by activated RNase L. In contrast, all of these effects are reduced
when RNA contains modified nucleosides. Unmodified RNA is therefore identified as a
distinguishing pattern for 2-5A system activity.
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3.2 Materials and methods
Cells and reagents
Immortalized wild-type (WT) and RNase L−/− mouse embryonic fibroblasts
(MEFs) were maintained in RPMI medium supplemented with 2 mM L-glutamine, 100
U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal calf serum. RNA oligos C11U2C7
and C11Ψ2C7 were custom synthesized (Dharmacon) and were 5’end-labeled using
adenosine 5'-[γ-32P]-triphosphate (γ-32P-ATP) (PerkinElmer) and T4 polynucleotide
kinase (New England Biolabs).

Immunoprecipitation
HEK293T cells were seeded into 96-well plates at a density of 5.0 × 104 cells/well
one day prior to transfection. Cells were exposed to 50 µl DMEM containing lipofectincomplexed RNA (0.25 µg) for 1 hour, which was then replaced with complete medium
and further cultured. Cells were incubated in methionine/cysteine-free medium
(Invitrogen) for 1 hour, then pulsed with complete medium supplemented with 35Smethionine/cysteine (140 mCi/mL) (PerkinElmer) for 3−5 hours prior to lysis in 50 µl
RIPA buffer supplemented with protease inhibitor cocktail (Sigma). Renilla luciferase
was immunoprecipitated from lysates using an anti-Renilla luciferase antibody (MBL)
and protein G-coated dynabeads (Invitrogen) and separated by 15% polyacrylamide gel
electrophoresis. Gels containing the labeled samples were treated with 1 M sodium
salicylate, dried, and a fluorogram was generated by exposure to BioMax MS film
(Kodak).
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RNA stability in rabbit reticulocyte lysate
Equal mass (25 ng/µl) or equal molar (40 µM) firefly and Renilla mRNAs were
incubated in 15 µl rabbit reticulocyte lysate (RRL, Promega) at 30°C. At the indicated
time a 2 µl aliquot was removed and the RNA was recovered using Trizol (Invitrogen)
for subsequent detection by northern blotting.

RNA stability in cell culture
HEK293T, WT MEF, or RNase L−/− MEF cells were nucleofected with 5 µg
mRNA using nucleofector program T-020 and nucleofector V kit (Lonza). After 15
minutes recovery in RPMI, cells were plated in complete media and incubated at 37°C.
At the indicated time, RNA was recovered from cells using Trizol (Invitrogen) for
subsequent detection by northern blotting.

Northern blotting
RNA was isolated from RRL or cells using Trizol (Invitrogen). To enhance the
RNA yield, 70 µg of glycogen (Roche Diagnostics) was added as carrier, and the
precipitation was performed in siliconized tubes at −20°C overnight. RNA samples were
denatured then separated in denaturing, 1.4% agarose, 0.22 M formaldehyde gel
submerged into MESA buffer (Sigma) supplemented with 0.22 M formaldehyde. RNA
was transferred to NYTRAN Nylon(+) membrane (Schleicher & Schuell) and UV crosslinked. The membranes were prehybridized at 68°C for 1 h in MiracleHyb (Stratagene).
To probe the northern blots, 50 ng of DNA was labeled using [α-32P]dCTP (Amersham
Biosciences) with a random prime labeling kit (Roche Applied Science). Probes were
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derived from plasmids and were specific for the coding region of firefly or Renilla
luciferase, or for a β-globin 5' UTR and 3' UTR sequence present in both mRNAs. The
membranes were hybridized at 68°C for 20 hours with MiracleHyb containing the labeled
and denatured probe. The membranes were washed and exposed to Kodak MS film using
an MS intensifier screen at −70°C for 2–72 hours or exposed to a phosphor-storage
screen and imaged using a Typhoon phosphorimager (GE Healthcare).

In vitro OAS activation
Recombinant human OAS1 p42 108, recombinant human RNase L 243, and
p3[2’p5’A]2A (2-5A3) 242 were prepared as described previously. Dual-labeled fluorescent
probe 6-FAM-UUA UCA AAU UCU UAU UUG CCC CAU UUU UUU GGU UUABHQ-1 was custom synthesized by Integrated DNA technologies. In vitro OAS1
activation was performed as previously described 243. Briefly, 20 µg/ml OAS1 was
activated with 2 µg/ml RNA for the indicated time in buffer consisting of 20 mM HEPES
pH 7.5, 20 mM MgOAc, 20 mM KCl, 1 mM EDTA, and 10 mM ATP. Reactions were
stopped by heating to 95°C for 3 minutes. Microcon YM-3 centrifugal filters (Millipore)
were used to separate 2-5A, and the 2-5A produced was then measured by mixing with 8
µg/ml RNase L and 0.1 µM fluorescent probe in RNase L cleavage buffer (consisting of
25 mM Tris-HCl pH 7.4, 100 mM KCl, 10 mM MgCl2, 50 mM ATP, and 7 mM βmercaptoethanol) and compared to the linear range of a standard curve generated using 0,
0.01, 0.03, 0.05, 0.1, 0.3, 0.5, 1, 3, 5 and 10 nM of purified 2-5A3. Fluorescent intensity is
proportional to 2-5A concentration.
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In vitro RNA cleavage by RNase L
Recombinant human RNase L 243, and p3[2’p5’A]2A (2-5A3) 242 were prepared as
described previously. For RNA oligos, 12.5 nM RNase L was activated on ice with 100
nM 2-5A3 for 30 minutes in RNase L cleavage buffer (consisting of 25 mM Tris-HCl pH
7.4, 100 mM KCl, 10 mM MgCl2, 50 mM ATP, and 7 mM β-mercaptoethanol). Then
100 nM 5’ end-labeled RNA oligo [32P]-C11U2C7 or [32P]-C11Ψ2C7 (Dharmacon) was
added and reactions were incubated at 30°C. At the indicated time, reactions were
stopped by the addition of urea-TBE loading buffer (BioRad) and heating to 95°C for 3
minutes. Aliquots were separated by 15% polyacrylamide gel electrophoresis, gels were
dried, and samples were imaged using a phosphor storage screen and detected using a
Typhoon phosphorimager. Cleavage of mRNA was performed similarly, using 10 nM
RNase L, 10 nM 2-5A3, and 100 nM mRNA. Reactions were stopped by heating to 95°C
for 5 minutes. The mRNA was recovered by phenol:chloroform extraction and detected
by northern blotting.

Translation of mRNA in mice
All mice were cared for according to institutional guidelines at the University of
Pennsylvania under a protocol approved by the Institutional Animal Care and Use
Committee. Wild-type C57Bl/6 (NCI) and C57Bl/6 backcrossed RNase L−/− mice at 9−16
weeks of age received tail-vein injections of 1 µg RNA complexed with lipofectin
(Invitrogen) in 60 µl DMEM. At the indicated time, mice were sacrificed and spleens
were isolated. Each spleen was bisected and spleen fragments were homogenized in 200
µl cell culture lysis reagent (Promega). Luciferase activity was detected in a 40 µl aliquot
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of cell culture lysis reagent using 200 µl luciferase assay substrate (Promega) and a
LUMAT LB 950 luminometer (Berthold) at a 10-second measuring time.

rRNA cleavage
One day prior to transfection, WT or RNase L−/− MEF cells were seeded into 96well plates at a density of 5.0 × 104 cells/well and treated with 1000 U/ml interferonαA/D (Sigma). Poly(I:C) or mRNAs were complexed with lipofectin (Invitrogen) as
described previously 130. Cells were exposed to 50 µl DMEM containing lipofectincomplexed RNA (2.5 µg) for 1 hour, which was then replaced with complete medium
and further cultured. At 3 hours post-transfection, total RNA was recovered from cells
using Trizol (Invitrogen). RNA was separated by agarose gel electrophoresis, stained
with SybrGold reagent (Invitrogen), and detected using UV fluorescence and a GelDoc
2000 imager (BioRad).
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3.3 Results
mRNA containing nucleoside modifications activates OAS less than unmodified
mRNA
We first compared the activation of purified human OAS1 by unmodified or
modified nucleoside-containing mRNA with identical sequence. Activation of OAS1 was
assessed by recovering the 2-5A produced, which was then quantified using a
fluorescence quenching assay. Unmodified mRNA activated OAS1, which was
significantly (p<0.05) reduced when the mRNA contained pseudouridine (Figure 3-1A).
Similar results were obtained when OAS activation was tested using a panel of mRNAs
containing the modified nucleosides m6A, m5C, or s2U (Figure 3-1B). Subsequent
experiments focused on the comparison of unmodified RNA to Ψ-containing mRNA with
identical sequence.

58

Figure 3-1. OAS activation by mRNA containing modified nucleosides
Purified human OAS1 p42 was activated by mixing with (A) unmodified (U) or Ψcontaining mRNA or (B) a panel of mRNAs containing the indicated nucleoside
modifications. Reactions were stopped at indicated times by heating at 95°C. Spin
columns were used to isolate the 2-5A produced in each reaction, and 2-5A levels were
assessed from an aliquot of each reaction using a fluorescence quenching assay. Asterisks
indicate P-value <0.05 compared to U-mRNA. Data shown are mean ±SEM of three
replicates in one experiment and are representative of three independent experiments. In
(B) SEM error bars were omitted for clarity.

59

Pseudouridine-containing mRNA induces less rRNA cleavage than unmodified
mRNA
OAS activation by pathogenic RNA leads to activation of RNase L, which
mediates the effector function of the 2-5A system by cleaving ssRNA. RNase L-mediated
cleavage at exposed loops of rRNAs in intact ribosomes results in well-defined cleavage
patterns in rRNA 264. Therefore, the integrity of rRNA following mRNA transfection was
examined. Lipofectin-complexed mRNA was transfected to WT and RNase L−/− MEF
cells, and total RNA was subsequently recovered and examined by agarose gel
electrophoresis and UV imaging. No RNA and the dsRNA analog poly(I:C) were
included as negative and positive controls, respectively. In WT cells, delivery of
unmodified in vitro transcribed mRNA induced cleavage of rRNA but rRNA cleavage
was reduced if the mRNA contained Ψ. In contrast, this rRNA degradation was not
observed in cells lacking RNase L (Figure 3-2).
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Figure 3-2. Induction of rRNA cleavage by in vitro transcribed mRNA
Unmodified (U) or Ψ-containing mRNA encoding firefly luciferase was complexed to
lipofectin and delivered to WT or RNase L−/− MEF cells, as were no RNA (−) and
poly(I:C) (+) controls. Three hours following transfection, total RNA was recovered from
cells. RNA aliquots were separated in an agarose gel and visualized by UV fluorescence.
Arrowheads indicate rRNA cleavage products. Representative data from one of three
independent experiments is shown.
RNase L cleaves uridine-containing RNA more readily than Ψ-containing RNA
Activated RNase L cleaves preferentially following UpNp in ssRNA. Therefore,
we next compared the ability of RNase L to cleave Ψ-containing RNA. Purified
recombinant human RNase L was activated with 2-5A3 and mixed with a 5’-[32P] endlabeled RNA oligo containing a single RNase L cleavage site (C11U2C7 or C11Ψ2C7).
Reaction products were gel separated to visualize RNA cleavage. The RNA oligo
containing unmodified uridine was rapidly cleaved, but there was no significant cleavage
of RNA oligo containing Ψ (Figure 3-3A and B). Full-length mRNA was then analyzed
for cleavage by RNase L. Both unmodified and Ψ-mRNA could be cleaved by RNase L.
However, consistent with the results obtained with RNA oligos, Ψ-containing mRNA
was cleaved at a slow rate by RNase L (Figure 3-3C).
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Figure 3-3. Cleavage of Ψ-containing RNA by RNase L
Purified RNase L was activated on ice by 2-5A3 prior to mixing with RNA substrates. (A)
Cleavage of RNA oligos [32P]-C11U2C7 (UU) or [32P]-C11Ψ2C7 (ΨΨ) by RNase L.
Reactions were stopped at the indicated time by addition of loading buffer, and reactions
were separated by PAGE and visualized by phosphor storage radiography. Representative
data from one of three independent experiments is shown. (B) Quantification of phosphor
storage intensities. Values were normalized to the values obtained in 30 minutes reactions
not containing RNase L. Data represents average ±SEM of n=3 experiments. Asterisks
indicate P-values <0.05 comparing UU to ΨΨ. (C) Cleavage of unmodified (U) or Ψcontaining mRNAs with identical sequence by RNase L. Reactions were stopped at
indicated times by heating to 95°C. Following phenol:chloroform extraction and
precipitation, aliquots from each reaction were assessed by northern blotting.
Representative data from one of three independent experiments is shown.
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RNase L facilitates enhanced translation of Ψ-containing mRNA in cells and after in
vivo administration
Because Ψ-modification of mRNA reduced activation of OAS1, rRNA
degradation, and mRNA cleavage by RNase L, we asked how the absence of RNase L
influences translation of unmodified and Ψ-containing mRNA. To do so, mRNAs
encoding luciferase were transfected into wild-type (WT) or RNase L−/− MEF cell lines
and translation was assessed by measuring luciferase activity. In WT cells, Ψ-containing
mRNA is translated to a greater level than unmodified RNA. However, in RNase L−/−
cells, the translational advantage of Ψ-mRNA over unmodified mRNA is dramatically
reduced (Figure 3-4A).
Similar patterns of translation occur in the spleens of mice following injection of
mRNA. Either WT C57Bl/6 or RNase L−/− mice were given lipofectin-complexed
luciferase mRNA by tail-vein injection. At sacrifice, luciferase activity was assessed in
spleen lysate. In WT mice, Ψ-containing mRNA is translated to higher levels than
unmodified RNA. In RNase L−/− mice, translation of Ψ-containing mRNA reached the
same level as observed in WT mice, but translation of unmodified mRNA is increased
relative to WT (p<0.05), (Figure 3-4B).
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Figure 3-4. Translation of unmodified and Ψ-containing mRNA in wild-type and
RNase L−/− cells and mice
Unmodified (U) or Ψ-containing in vitro transcribed mRNA encoding firefly luciferase
was complexed to lipofectin and delivered to wild-type (WT) and RNase L−/− (RL−/−)
MEF cells or mice. Luciferase activity was assessed in aliquots of cell lysate. (A) MEF
cells lysed at 5 hrs following transfection. Luciferase relative light unit (RLU) values
were normalized to the RLU obtained with unmodified mRNA (indicated by dashed line)
and expressed as fold increase. Error bars indicate SEM of quadruplicate wells from one
representative of at least six independent experiments. (B) Lipofectin-complexed mRNA
was delivered by tail-vein injection into mice. At 4 hours following delivery, mice were
sacrificed and spleens were lysed. Values presented are luciferase relative light units
(RLU) in 1/5 of the total 200 µl lysate. Error bars represent SEM of n = 3 mice.

Pseudouridine-containing mRNA is actively translated longer than unmodified
mRNA
We next compared translation over time, to determine how modified nucleosides
influence the duration of translation. RNA was complexed to lipofectin and delivered to
cells, which were then pulsed with 35S-methionine/cysteine at different times after
transfection, and translation of the mRNA was assessed by immunoprecipitation of the
encoded Renilla luciferase protein. As previously observed, there was a higher level of
translation of Ψ-containing mRNA at each time point (Figure 3-5A). In addition, the
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translation of Ψ-containing mRNA continued after measurable translation of unmodified
mRNA ceased, persisting at 48 hours (Figure 3-5B).

Figure 3-5. Translation of Ψ-containing mRNA in cell culture
Unmodified (U) or Ψ-containing mRNA was complexed to lipofectin and delivered to
HEK293T cells. Cells were subsequently pulsed with 35S-methionine/cysteine prior to
lysis. (A) Renilla luciferase activity was assessed in aliquots of cell lysate. Data displayed
is mean ± SEM from four replicates, each performed in duplicate. (B) Renilla luciferase
protein was immunoprecipitated from cell lysates and PAGE separated prior to radiofluorography. Data shown is one of four replicates and is representative of three
independent experiments.

Nucleoside-modified mRNA has an increased half-life
The extended translation of Ψ-modified RNA demonstrated that the RNA
persisted in a functional state for an extended period of time. Accordingly, we examined
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the stability of unmodified and Ψ-containing mRNA by northern blot analysis. Both
unmodified and Ψ-mRNA were equally stable at room temperature through experimental
time-courses and indefinitely in storage at −20°C (data not shown). Unmodified and ΨmRNAs were added to rabbit reticulocyte lysate (RRL) or transfected to HEK293T cells.
When transfecting cells using cationic lipids, a portion of RNA complexed with
transfection reagents persists as an extracellular, nuclease-protected fraction. Therefore,
for these experiments, we used nucleofection to deliver naked mRNA and confirmed the
rapid degradation of extracellular RNA by serum nucleases in the culture media (data not
shown). Total RNA was subsequently re-isolated, and aliquots were examined by
northern blot to compare degradation rates of the reporter mRNAs. Two reporter mRNAs
were studied simultaneously, to ensure that stability differences were not a result of
differences in coding sequence. As shown in figure 3-6, Ψ-modified mRNAs had longer
half-lives than unmodified mRNAs both in RRL (Figure 3-6A) and in HEK293T cells
(Figure 3-6B).
Subsequently, the influence of RNase L on the stability of unmodified and Ψcontaining mRNA was also compared using RNase L−/− MEF cells. As in HEK293T cells,
the mRNA was delivered by nucleofection. Total RNA was recovered from cell culture
and firefly and Renilla luciferase mRNA were assessed by northern blot. In both WT and
RNase L−/− MEF cells, Ψ-modified mRNA had an increased half-life compared to
unmodified RNA (Figure 3-6C).
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Figure 3-6. Half-life of Ψ-containing mRNA
(A and B) Unmodified (U) or Ψ-containing mRNAs encoding firefly or Renilla luciferase
proteins were mixed 1:1 and either added to RRL (A) or nucleofected to HEK293T cells
(B). At the indicated time points, RNA was recovered using Trizol reagent. RNA was
subsequently detected in aliquots of the recovered RNA by northern blotting. Data shown
is representative of at least five independent experiments. (C) Unmodified (U) or Ψcontaining in vitro transcribed mRNA encoding firefly luciferase was delivered to wildtype (WT) or RNase L−/− MEF cells by nucleofection. Cell were lysed at 0.2, 1, 3, 6, or
24 hrs following transfection, total RNA was recovered, and luciferase mRNA was
assessed by northern blotting. Representative data is shown from one of three
independent experiments.
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3.4 Discussion
Here, we identify novel impacts of nucleoside modifications in RNA on the 2-5A
pathway. Our data show that conventional in vitro transcribed mRNA activates OAS1,
but this activation is reduced when mRNA contains modified nucleosides. OAS
activation by unmodified RNA leads to RNase L-mediated rRNA cleavage in cells,
which is not induced by Ψ-mRNA. Furthermore, we demonstrate reduced RNase L
cleavage of Ψ-containing RNA. Experiments using RNase L−/− MEF cell culture and
following injection in RNase L−/− mice demonstrate that translation of unmodified mRNA
is decreased in the presence of the intact 2-5 system, but the translation level of ΨmRNA is largely independent of the 2-5A system. In addition, we demonstrate that
incorporation of Ψ increases the half-life of in vitro transcribed mRNA in cells and
lysates. Finally, Ψ-containing mRNA is translated for a longer duration than unmodified
in vitro transcribed mRNA.
RNA sensing in the 2-5A pathway is performed by the OAS family of proteins.
OAS was originally characterized as requiring >8 base-pairs (bp) of uninterrupted helix
in >30 bp-long dsRNA 167, but activation has also been demonstrated by a variety of
ssRNAs, including aptamers 109, viral RNAs 63, 169, 226, 247, and some cellular RNAs 168, 187.
RNAs containing 2’-O-methylation 166, 217 or 5-methyluridine 9 do not activate OAS. Here,
we report that unmodified in vitro transcribed RNA activated OAS1 to produce 2-5A, but
this was substantially reduced when RNA contained Ψ, m6A, m5C, or s2U. Recently, the
consensus sequence nnWWnnnnnnnnnWGn (W = U or A) was demonstrated to be
important for OAS1 activation by dsRNA, and this interaction is dependent on the minor
groove and free OH groups on the critical base pairs 139. The requirement that three out of
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the four critical base-pairs in this sequence be U:A highlights the importance of uridine
for OAS1 activation. However, pseudouridine does not disrupt base-pairing to adenosine
and the imino group of Ψ is oriented toward the major groove 101, so how Ψ disrupts
OAS1 activation remains unclear. The presence of Ψ stabilizes secondary structure and
adds rigidity to both ss and dsRNA (reviewed in 43). In this capacity, Ψ could affect OAS
activation by altering the equilibrium structure of the RNA, rather than directly affecting
OAS binding.
Production of 2-5A by activated OAS results in activation of the latent
endoribonuclease RNase L, which is the effector protein of the 2-5A pathway. Activated
RNase L cleaves various ssRNA including accessible sites in rRNA, resulting in specific
cleavage products visible by gel electrophoresis 264. Therefore, we examined the rRNA
cleavage induced in cells by transfection of in vitro transcribed mRNA. In WT MEF,
unmodified mRNA induced rRNA cleavage, which was reduced if mRNA contained Ψ.
However, no RNA caused rRNA cleavage in RNase L−/− cells, confirming that the 2-5A
system is required for RNA-induced rRNA cleavage. High levels of 2-5A result in global
rRNA cleavage by RNase L 149, and when sustained, ultimately lead to apoptosis 40, 281. In
comparison, the level of rRNA cleavage induced here by transfection of in vitro
transcribed mRNA is relatively small, and may not be expected to induce high levels of
apoptosis. On the other hand, this level of rRNA cleavage is sufficient to have a profound
impact on translation of the reporter mRNA. We propose that unmodified RNA induces
local OAS and RNase L activation, as demonstrated with viral RNAs and ssRNA
covalently linked to dsRNA 8, 186. Accordingly, locally-activated RNase L cleavage likely
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reduces translation of unmodified RNA through local cleavage of rRNA without inducing
global rRNA cleavage and apoptosis.
The presence of Ψ has been shown to enhance the stability of RNA secondary
structures, but has not previously been demonstrated to cause resistance to nucleases. The
presence of Ψ did not inhibit cleavage by the nucleases RNase A, RNase H 279, RNase T1,
RNase T2, nuclease P1, and snake venom phosphodiesterase, although there is some
indication that pancreatic diesterase and snake venom phosphodiesterase may cleave with
reduced efficiency180. A previous report based on cleavage of a C11N2C7 RNA oligo
showed that RNA containing 2’-deoxy-2’-α-fluorouridine was bound by RNase L but
cleaved slowly, whereas RNA containing 2’-O-methyluridine was not bound by RNase L
250

. Here, we used a similar approach and demonstrated that purified RNase L readily

cleaved the ssRNA oligo C11U2C7 but not when the cleavage site contained Ψ. We also
extended those findings to the examination of long in vitro transcribed mRNA and
showed that unmodified mRNA was cleaved by purified RNase L, but cleavage of ΨmRNA proceeded more slowly. The slow cleavage of Ψ-mRNA despite inactivity toward
C11Ψ2C7 is not surprising given RNase L's loose sequence specificity. Although RNase L
cleaves preferentially following UpNp, with highest activity following UU and UA, it is
also capable of cleaving following AU, AA, AC, and CA but not CC 38, 84, 265.
As seen in previous reports 3, 131, in wild-type cells there was dramatically higher
translation of Ψ-mRNA than unmodified mRNA. By contrast, in RNase L−/− MEF cells,
the enhanced translation of Ψ-mRNA was modest. Similarly, the translational advantage
of Ψ-mRNA was reduced in RNase L−/− mice. Notably, however, the absolute translation
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level of Ψ-mRNA remained equal in WT and RNase L−/− mice, while the translation of
unmodified mRNA increased in RNase L−/− mice. This indicates that neither the presence
of RNase L nor Ψ-mRNA alone significantly affects translation, but rather that
unmodified RNA causes translational inhibition through RNase L activation. Moreover,
these results are consistent with the in vitro activation of OAS1 by unmodified RNA that
we observed.
We also examined the effect of Ψ-modification on the stability of in vitro
transcribed mRNA. In RRL and in cell culture, Ψ-mRNA was degraded more slowly than
unmodified mRNA. Previous experiments also suggested that Ψ-mRNA is retained
longer following injection in mice 131. Despite the rapid cleavage of unmodified RNA by
RNase L in vitro, the half-life of unmodified RNA did not increase to the level of ΨmRNA in RNase L−/− cells. This suggests that in addition to RNase L, other intracellular
nucleases also cleave unmodified RNA more efficiently than Ψ-containing RNA.
The RNase L gene is genetically linked to prostate cancer and individuals
homozygous for the R462Q mutant of RNase L, which exhibits reduced catalytic activity,
are at increased risk for developing prostate cancer 39. The established role of RNase L as
an antiviral effector lead to speculation regarding a viral etiology in prostate cancer.
Subsequently, a novel gammaretrovirus, xenotropic murine leukemia virus-related virus
(XMRV), was discovered in prostate tumors from RNase L-R462Q homozygous patients
252

. RNase L dysfunction has also been reported in association with chronic fatigue

syndrome (CFS) 237, and CFS has also recently been linked to XMRV 150. IFN-β inhibits
XMRV replication, and this action is mediated in part by RNase L activity 69. Nucleoside
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modifications are found in viral mRNAs, including reports of hyper-modification 179.
However, the presence of modified nucleosides in XMRV viral RNA (vRNA) has not
been investigated. Because RNA modifications reduce 2-5A system activity, nucleoside
modifications in XMRV vRNA could contribute to the development or progression of
prostate cancer and CFS.
Nucleases play a central role in host defense through destruction of pathogenic
nucleic acids. The 2-5A system functions to detect and degrade danger-associated
intracellular RNAs. Activation of RNase L also leads to reduced translation due to rRNA
cleavage and when sustained, results in apoptosis, providing further limitations to
pathogen replication. Here, we identify unmodified RNA as a molecular pattern
recognized by OAS and RNase L. However, 2-5A system activity is decreased when
RNA contains nucleoside modifications, which reduce both OAS activation and cleavage
by RNase L. We propose that modified nucleosides are a general pattern, which facilitate
recognition of danger-associated RNA as distinct from endogenous cellular RNA, as part
of the extensive system of innate host defense against pathogenic RNA.
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CHAPTER 4

Nucleofection induces eIF2α
α phosphorylation mediated by GCN2 and PERK
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4.1 Introduction
Nucleofection is an advanced electroporation technique which varies electrical
parameters and buffers to optimize delivery for specific cell types with high efficiency
and reproducibility 96. A major advantage of nucleofection is its versatility in transfecting
a wide variety of primary and non-dividing cell types 96, 102, 107. Nucleofection can be used
to deliver a variety of nucleic acids including mRNA 51, 254, siRNA 96, 220, miRNA 199, 259,
cDNA 25, and DNA plasmids 102, 211.
An increasingly common use of nucleofection is delivery of mRNA. Gene
transfer based on mRNA is safe, because unlike DNA-based and viral vector approaches
100

, mRNA-based gene transfer does not bear the risks of chromosomal integration.

Protein expression is fast, beginning immediately upon mRNA reaching the cytoplasm.
High transfection efficiency can be obtained, in part because there is no requirement for
mRNA to reach the nucleus. Unlike other gene delivery strategies, no additional
transcripts are made following transfection, so translation rates following delivery are a
key consideration for mRNA-based gene delivery applications.
We recently reported enhanced translation of in vitro transcribed mRNA
containing Ψ 131, which results in part from reduced phosphorylation of eukaryotic
initiation factor 2-alpha (eIF2α) 3. Phosphorylation of eIF2α reduces functional
translation initiation complexes, resulting in a general decrease in translation initiation
events and therefore a global decrease in translation (see 114 for review). There are four
known eIF2α kinases in mammalian cells, each responding to different forms of cellular
stress: RNA-dependent protein kinase (PKR), PKR-like ER kinase (PERK), general
control non-derepressible-2 (GCN2), and heme-regulated inhibitor (HRI). Activation of
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PKR occurs upon binding to double-stranded (ds)RNA and in this capacity is primarily
characterized as an anti-viral sensor, although it also plays additional roles 3, 88. HRI is
active primarily in erythroid cells during heme deprivation. PERK is activated under
conditions of ER stress as part of the unfolded protein response. GCN2 is stimulated by a
variety of stresses, including amino acid starvation, proteosome inhibition, and UV
irradiation 64.
Here, we show that nucleofection alone induces phosphorylation of eIF2α. We
identify GCN2 as an eIF2α kinase contributing to this phosphorylation. Preliminary data
also suggests that the involvement of PERK in this nucleofection-induced
phosphorylation. Further studies are ongoing to confirm the involvement of PERK, and to
measure translational repression following nucleofection. Developing approaches to
overcome nucleofection-induced eIF2α phosphorylation will enhance the continued
progression of mRNA-based therapies.
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4.2 Materials and methods
Cells and reagents
Immortalized mouse embryonic fibroblasts (MEFs) were generously provided by
David Ron (WT, GCN2−/−, and PERK−/−), Robert Silverman (PKR−/−), and Alan Diehl
[with permission from Douglas Cavener] (PERK/GCN2−/−). MEFs were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mM L-glutamine
(Life Technologies), 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen), and
10% fetal calf serum (HyClone), MEM non-essential amino acids (Invitrogen), and 55
µM β-mercaptoethanol (BioRad).

Nucleofection
MEF cells were nucleofected using program T-020 and nucleofector V kit
(Lonza). After 15 minutes recovery in RPMI, cells were plated in complete media and
incubated at 37° C. At the indicated time following nucleofection, cells were lysed in
RIPA lysis buffer supplemented with protease inhibitor cocktail (Sigma) for western
blotting.

Lipid and polymer transfections
Cells were seeded into 48-well plates at a density of 1.0 × 105 cells/well one day
prior to transfection. Cells were exposed to 50 µl DMEM containing lipid-based
lipofectin (Invitrogen), 50 µl DMEM medium alone, or 200 µl complete DMEM medium
containing polymer/lipid-based TransIT-mRNA (Mirus) for 1 hour, which was then
replaced with complete medium and further cultured. At the indicated time following
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RNA transfection, cells were lysed in RIPA lysis buffer supplemented with protease
inhibitor cocktail (Sigma) for western blotting.
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4.3 Results
Nucleofection induces eIF2α
α phosphorylation in WT MEF cells
The impact of nucleofection on translation was first studied in a MEF cell line
derived from wild-type (WT) C57Bl/6 mice. Nucleofection conditions were optimized
according to manufacturer guidelines, and it was determined that program T-020
provided the best cell survival with high transfection efficiency (data not shown). WT
MEF were then nucleofected without including any nucleic acid in the transfection mix.
As a negative control, cells were mock treated by subjecting them to the same
manipulation and buffers but without electric shock. Following nucleofection, eIF2α
phosphorylation was assessed by western blotting using an antibody specific for eIF2α
phosphorylated at serine 51. As shown in Figure 4-1, nucleofection induced
phosphorylation of eIF2α four-fold over the baseline level present in mock-treated cells.
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Figure 4-1. Phosphorylation of eIF2α
α in wild-type cells following nucleofection
Wild-type MEF cells were nucleofected or mock-treated, then lysed at the indicated times.
(A) Phosphorylation of eIF2α was assessed in aliquots of lysate by western blotting with
antibody specific for phosphorylated eIF2α (eIF2α−(P)) and then re-probed for total
eIF2α. Representative data from one of three independent experiments is shown. (B)
Quantification of western blot band densities. Values were calculated as the ratio of
phosphorylated to total eIF2α and normalized to the values obtained in mock-treated
cells at 0.1 hours post-shock. Data displayed is mean ± SEM of n = 3 experiments.
Lipid and polymer transfection reagents do not induce eIF2α
α phosphorylation in
WT MEF cells
To determine if eIF2α phosphorylation is a common feature of transfection,
eIF2α phosphorylation was measured following treatment with lipid and polymer
transfection reagents. Reagents were prepared and delivered according to manufacturer
instructions, but without including nucleic acid in the transfection mixes. Neither lipid-
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based nor polymer-based transfection protocols induced phosphorylation of eIF2α
(Figure 4-2).

Figure 4-2. Phosphorylation of eIF2α
α in wild-type cells following transfection
Wild-type MEF cells were transfected with the indicated transfection reagent or mocktreated and lysed at the indicated time points. (A) Phosphorylation of eIF2α was assessed
in aliquots of lysate by western blotting. Representative data from one of two
independent experiments is shown. (B) Quantification of western blot band densities.
Values were calculated as the ratio of phosphorylated to total eIF2α and normalized to
the values obtained in mock-treated cells at 0.1 hours post-shock. Data displayed is mean
± SEM of n = 2 experiments.
GCN2−/− delays and reduces nucleofection-induced eIF2α
α phosphorylation
Of the four mammalian eIF2α kinases, three — PKR, PERK, and GCN2 — are
widely distributed, whereas HRI is reported to function primarily in erythroid cells 151.
Therefore, to identify the eIF2α kinase responsible for the nucleofection-induced eIF2α
phosphorylation, we took advantage of MEF cell lines created from mice deficient in
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PKR, PERK, and GCN2. As was done with WT MEF, cells were nucleofected and eIF2α
phosphorylation was assessed by western blotting. Nucleofection of PKR−/− MEF cells
resulted in eIF2α phosphorylation comparable to that induced in WT MEF cells (Figure
4-3A), as did nucleofection of PERK−/− MEF cells (Figure 4-3B). Nucleofection also
induced eIF2α phosphorylation in GCN2−/− MEF cells, but the peak level of
phosphorylation was reduced and occurred later than in other cell lines (Figure 4-3C).
Mock treatment did not induce eIF2α phosphorylation in any cell line (Figure 4-3).
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Figure 4-3. Phosphorylation of eIF2α
α in kinase-deficient cells following
nucleofection
MEF cells deficient in eIF2α kinases, PKR−/− (A), PERK−/− (B), or GCN2−/− (C) were
nucleofected or mock-treated, then lysed at the indicated time points. Phosphorylation of
eIF2α was assessed in aliquots of lysate by western blotting. Representative data of 2–4
independent experiments is shown.
GCN2 and PERK are responsible for nucleofection-induced eIF2α
α phosphorylation
The removal of single eIF2α kinases did not completely prevent nucleofectioninduced eIF2α phosphorylation, suggesting the possibility that multiple kinases are
involved. Therefore, we assessed phosphorylation of eIF2α following nucleofection of
MEF cells derived from a dual-knockout GCN2−/−/PERK−/− mouse. No eIF2α
phosphorylation was visible in dual-knockout GCN2−/−/PERK−/− MEF cells (Figure 44A). Of interest, a dramatically reduced baseline level of eIF2α phosphorylation was
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observed in these cells. The dual knockout cells responded to poly(I:C) demonstrating
functional PKR and the ability of their eIF2α to be phosphorylated (Figure 4-4B). These
data demonstrate that both GCN2 and PERK are responsible for nucleofection-induced
phosphorylation of eIF2α.
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Figure 4-4. Phosphorylation of eIF2α
α in dual-knockout cells following nucleofection
−/−
−/−
(A) GCN2 /PERK MEF cells were nucleofected or mock-treated, then lysed at
indicated time. Phosphorylation of eIF2α was assessed in aliquots of lysate by western
blotting. (B) GCN2−/−/PERK−/− MEF cells were treated with poly(I:C) or mock treated
and then lysed four hours following transfection. Phosphorylation of eIF2α was assessed
in aliquots of lysate by western blotting and quantified. Band intensities are represented
as the ratio of phosphorylated to total eIF2α, expressed as fold increase over eIF2α
phosphorylation in mock treated cells (indicated by the dashed line).
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4.4 Discussion
We demonstrate that nucleofection induces phosphorylation of eIF2α. In studies
using knockout cell lines, we identify GCN2 and PERK as the kinases responsible for the
remaining nucleofection-induced phosphorylation of eIF2α. The experiments in dualknockout cells will be repeated to confirm this finding. We identify that the electrical
shock component of nucleofection leads to the activation of GCN2 and PERK and
subsequent phosphorylation of eIF2α. This is demonstrated by the lack of induced eIF2α
phosphorylation in mock-treated cells, which were subjected to the same handling and
buffers as nucleofected cells. This effect of electrical shock has not been previously
reported and could be a common feature of electroporation or may be a specific effect of
nucleofection. Underhill et al. 251 examined eIF2α phosphorylation following
electroporation, but did not observe an increase unless DNA was also included in the
electroporation. Similarly, data reported by Tesfay et al. did not find substantial
phosphorylation of eIF2α following electroporation 241. However, it is likely that the
timing and level of eIF2α phosphorylation induced by electrical shock will vary with the
electrical parameters.
In single-knockout cell lines, the absence of GCN2 had a pronounced effect on
nucleofection-induced eIF2α phosphorylation, while no effect was observed with the
absence of PERK alone. Additionally, the kinetics of eIF2α phosphorylation were unique
in GCN2−/− cells, where there was little initial phosphorylation of eIF2α, which then
increased to peak at 2 hours following nucleofection. In PERK−/− cells, on the other hand,
the pattern of eIF2α phosphorylation was similar to that observed in WT cells.
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Elimination of nucleofection-induced eIF2α phosphorylation required the absence of
both GCN2 and PERK. Together these data suggest that the initial phosphorylation of
eIF2α is mediated through GCN2, which is subsequently supplemented by increasing
PERK activity.
GCN2 is activated by a range of stresses, including nutrient limitation,
proteosome inhibition, oxidizing conditions, high salinity, and UV irradiation. In all cases,
it is thought that GCN2 activation requires the binding of uncharged tRNA to GCN2 (see
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). In contrast to WT cells, in GCN2−/− cells, we observed only low level eIF2α

phosphorylation at the earliest time point following nucleofection, suggesting that
nucleofection has an immediate impact on the availability of charged tRNAs.
PERK is an ER-associated transmembrane protein that normally exists inactive as
a heterodimer with the chaperone BiP. ER stresses, such as excess misfolded protein,
cause dissociation of BiP from PERK, allowing PERK homodimerization and activation
19

. The absence of nucleofection-induced eIF2α phosphorylation in GCN2−/−/PERK−/−

cells suggests that the phosphorylation of eIF2α seen in GCN2−/− cells results from
PERK activation and occurs later than GCN2 activation following nucleofection.
Nucleofection may directly cause ER stress leading to PERK activation. Alternatively,
nucleofection-induced PERK activation may occur only in the absence of GCN2. In this
scenario, GCN2 activation following nucleofection results in translational repression.
However, in the absence of GCN2, unrepressed translation leads to ER stress and PERK
activation. Examining GCN2 and PERK phosphorylation in WT cells and comparing
PERK phosphorylation in WT and GCN2−/− cells would clarify if PERK activation is a
primary consequence of nucleofection or a secondary consequence of GCN2-knockout.
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In MEF cells, the level of nucleofection-induced eIF2α phosphorylation typically
returned to baseline levels by four hours following nucleofection, although in some cases
extended through 24 hours (data not shown). Given this timeframe, transgene expression
following delivery of mRNA is likely to be affected most dramatically, although early
expression following plasmid transfection would be impacted as well. Numerous
therapeutic approaches using mRNA delivery are under exploration, including
transfection of dendritic cells (DCs) with mRNA encoding tumor antigens 92, delivery of
mRNA encoding vaccine antigens 192, cancer immunotherapy through transfection of T
cells with mRNA encoding chimeric antigen receptors (CAR) 22, stem cell research 198,
and induced pluripotent stem (iPS) cell generation 4, 126, 238, 261, 266. Notably, nucleofection
delivery has now translated into ongoing clinical trials.
In addition to reducing translation of a transfected gene, eIF2α phosphorylation
has a general impact by repressing global translation in cells. This is of particular concern
for nucleofection of primary cells, which are often more fragile, and where minimal
disturbance is requisite. Therefore, my ongoing studies are examining nucleofectioninduced eIF2α phosphorylation in human PBMC, DC, and CD4+ T cells. Multiple current
trials employ nucleofection of patient’s cells for re-administration and minimizing
cellular stress to maximize cell survival is important to these approaches.
To achieve maximum benefit from nucleofection, it will be valuable to design
methods to obviate nucleofection-induced eIF2α phosphorylation. When serine 51 of
eIF2α is mutated to alanine (eIF2α-S51A), eIF2α cannot be phosphorylated, and
therefore is unaffected by eIF2α kinase activity, allowing ongoing translation despite
eIF2α kinase activation 221, 276. Co-delivery of mRNA encoding eIF2α-S51A with an
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mRNA transgene of interest would generate an increasing pool of non-phosphorylated
eIF2α which could offset nucleofection-induced eIF2α phosphorylation. A similar
approach was seen to enhance translation following delivery of plasmid DNA 251. Due to
the long half-life of eIF2α, estimated as 10 days 75, this approach would be expected to
have a long-lasting impact in transfected cells. Similarly, mRNA encoding inhibitors of
eIF2α kinases, such as the vaccinia K3L protein 134, could be co-transfected with an
mRNA of interest to limit eIF2α phosphorylation. Alternatively, mRNA transcripts could
be designed to take advantage of eIF2α phosphorylation rather than attempting to prevent
it. In contrast to the majority of transcripts, translation of select cellular mRNAs is
upregulated following eIF2α phosphorylation, including GCN4 174 and ATF4 106, and this
property is dependent on the 5’ UTR of these transcripts. Producing in vitro transcribed
mRNAs containing the GCN4 5’UTR might therefore allow selective translation through
the duration of eIF2α phosphorylation following nucleofection.
In summary, we demonstrate that nucleofection of cells stimulates transient
phosphorylation of the translation initiation factor eIF2α, mediated by GCN2 and PERK.
Phosphorylation of eIF2α, in general, results in inhibition of translation, limiting
translation of transfected mRNA and causing cell stress. These consequences have
important implications in the design and delivery of nucleic acid-based therapies.
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CHAPTER 5

Conclusions, implications, and future directions

5.1 Summary of results
Cells possess multiple pathways to detect and defend themselves from the danger
of exogenous RNA. Here, we establish that exogenously delivered in vitro transcribed
mRNA activates two of these systems, PKR and the 2-5A system. We further
demonstrate that the presence of modified nucleosides in RNA reduces the activation of
these RNA sensors, as well as the ability of RNase L to cleave modified RNA. The
activation of these systems results in an inhibition of translation of the unmodified in
vitro transcribed mRNA. In contrast, translation of mRNA containing modified
nucleosides remains high as a consequence of reduced PKR and OAS activation. In
addition, incorporation of modified nucleosides increases the in vivo half-life of mRNA.
Prompted by studies of mRNA transfection methods, we also show that nucleofection
induces phosphorylation of eIF2α. This effect is independent of mRNA delivery and is
mediated through activation of GCN2 and PERK.

5.2 RNA danger recognition
The presence of modified nucleosides in RNA reduces the activity of PKR, OAS,
and RNase L compared to unmodified RNA. Previous reports have indicated similar
results for other RNA sensors, TLR3, TLR7, TLR8 and RIG-I. Together, these data
support an interpretation that the absence of modified nucleosides in RNA is a common
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pattern recognized by RNA-responsive host defense sensors. Furthermore, this is
consistent with the precedent set by the identification of non-methylated CpG DNA as
the ligand for activation of TLR9. A conceptually similar but mechanistically distinct
approach is also used by some bacteria, which methylate portions of their own genome.
This protects their DNA, whereas external, unmethylated DNA is recognized and
degraded by restriction enzymes.
The frequency and types of nucleoside modifications found in RNA increase in
parallel with evolutionary complexity. Accordingly, mammalian RNA contains many
more modified nucleosides than bacterial RNA. Consequently, the paucity of modified
nucleosides in bacterial RNA serves as a molecular pattern for recognition by mammalian
RNA sensors 130. Similar to bacterial RNA, mtRNA contains few modified nucleosides.
During apoptosis mtRNA is degraded, but is not degraded in necrotic cell death. RNA
from necrotic cells activates DC more than RNA from apoptotic cells. Again, in this
scenario the presence of unmodified RNA may function as a danger signal recognized by
innate RNA sensors.
Uridine has been reported to be especially important for immunostimulation by
RNA 231 and has been identified as an important contributor to activation of TLR7 and
RIG-I 66, 67, 111, 116, 253, and immunostimulation is reduced by modification of uridine 115,
130, 131, 219, 231

. Consistent with these reports, we saw that the uridine modification Ψ had

the largest impact on mRNA translation, and that RNA containing the uridine
modification s2U was the least activating to PKR and OAS.
The functions of nucleoside modifications in RNA are not well understood.
Although some modification sites play important structural roles in tRNA and rRNA, no
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specific function has been identified for most sites of nucleoside modification. A
contributing factor in the evolutionary development and maintenance of nucleoside
modifications in RNA may be the ability to mark self-RNA and distinguish it from
pathogenic RNA. Consistent with this proposal, previous work in our lab demonstrated
that mammalian tRNA, which is highly modified, does not induce tumor necrosis factor
(TNF)α secretion by DC. Here, we additionally demonstrate that mammalian tRNA does
not activate PKR. In contrast, mammalian poly(A) purified mRNA induced little TNFα
secretion by DC but did activate PKR in vitro. Mammalian mRNA contains relatively
few modified nucleosides and, therefore, other mechanisms may be needed to prevent its
recognition by PKR and other RNA sensors. From this standpoint, nucleoside
modification is likely to function in concert with RNA capping, protein-coating of RNA,
compartmentalization of RNA sensors, and RNase-mediated control.

5.3 Roles of modified nucleosides in pathophysiology
Hyper-modification of viral RNAs has been reported, with viral RNAs containing
1−15 m6A compared to 3−5 in mammalian mRNAs 27, 179. Adenosine m6A modification
has been reported for adenovirus, avian sarcoma virus, reovirus, herpes simplex virus
(HSV)1, influenza, Rous sarcoma virus, and simian virus 40 36, 127, 143, 172, 234; and m5C
was reported in the mRNA from Sindbis virus and adenovirus 72, 234. Uniquely, turnip
yellow mosaic virus RNA contains Ψ and m5U 14. Methylation of viral RNA occurs
during the nuclear phase of the viral life cycle, and thus has not been reported for viruses
that replicate exclusively in the cytoplasm. Increased nucleoside modification would
benefit viruses by preventing immune activation by viral RNAs, and, therefore, may
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represent an immune evasion strategy. In contrast to viruses, the level of nucleoside
modification in bacterial RNA is vastly reduced as compared to mammalian RNA. In the
studies leading up to this dissertation, it was shown that the presence of Ψ in mRNA
prevented translation in E. coli lysate 131. Therefore, bacteria may be unable to use the
strategy of increased nucleoside modification due to other functional limitations, such as
intolerance of nucleoside modifications by the bacterial translation apparatus. To address
this possibility, it would be valuable to perform studies examining bacterial translation of
mRNA containing m6A and m5C, which are naturally-occurring components of
eukaryotic mRNA. However, bacteria have taken advantage of nucleoside modifications
to develop resistance to antibiotics. Bacteria introduce additional sites of nucleoside
modification, primarily methylation, into functionally relevant rRNA sites. These
modifications sterically block drug binding and thereby prevent drug activity 71.
RNA modification and RNA-modifying enzymes also contribute to genetic and
autoimmune diseases. Dyskeratosis congenita, mitochondrial myopathy, and sideroblastic
anemia each result from mutations in pseudouridine synthases 34, 271. The expression level
of TLR7 is linked to the development of systemic lupus erythematosus (SLE) 197, 228.
Fibrallarin, a 2’-O-methylating enzyme, is an autoantigen in autoimmune rheumatoid
arthritis, SLE, and systemic sclerosis (reviewed in 132), although the role of RNA
methylation has not been explored. With these conditions as precedents, RNA sensors
and RNA-modifying enzymes may be involved in other autoimmune conditions as well.
In light of the role that nucleoside modifications play in limiting RNA sensor activation,
defects in RNA-modifying enzymes should be investigated as risk factors or disease
modulators in the development and progression of autoimmune diseases.
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5.4 Implications for therapeutic RNA delivery
Gene therapy approaches based on mRNA delivery have advantages over plasmid
and viral-vector based delivery 28, 192, 204, 267. The safety profile for mRNA delivery is
excellent, as there is no danger of replication or recombination. RNA cannot integrate
into the host genome, which is an inherent risk for plasmid and viral vectors. Having no
protein component, mRNA-based delivery avoids the problems of adaptive immunity that
limit viral-based delivery. Manufacturing of mRNA is simple and easily scalable.
Because mRNA does not need to reach the nucleus, unlike plasmids and some viral
vectors, the transfection efficiency of mRNA is high even in primary and non-dividing
cells. Protein expression from mRNA is very rapid, beginning within minutes of
transfection. Translation from mRNA is directly proportional to the amount of mRNA
delivered, allowing dose-dependent control of transgene expression. Gene size
restrictions are prohibitive for some vector strategies, but are not an issue for mRNA. The
transient nature of mRNA – typical intracellular mRNA half-lives are only hours to days
– can be beneficial as well, allowing temporal control of gene expression and cessation of
treatment in the event of an adverse reaction. This would be especially beneficial for
applications such as iPS cell generation, where temporary expression is required but
long-term expression and retention of the vector are undesirable 4, 261, 266.
Use of mRNA containing modified nucleosides retains these valuable features of
mRNA-based therapy and also benefits from additional advantages. Delivery of mRNA
containing modified nucleosides would permit a reduced dose, due to enhanced protein
expression from each transcript. Modified mRNA persists and is translated longer, due to
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enhanced stability, which would decrease the frequency of administration needed for
long-term replacement. Activation of RNA sensors is reduced by nucleoside
modifications, and therefore modified RNA avoids unwanted side effects including
inhibition of cellular translation, rRNA cleavage, and pro-inflammatory signaling.
Additionally, decreased activation of RNA sensors also reduces the risk of developing
adaptive immune responses against the encoded protein(s).
When mRNA is used to deliver a vaccine antigen, it has been proposed that
immunostimulation by the RNA could contribute to developing the desired adoptive
immune response. Because nucleoside modifications reduce RNA immunogenicity, if
modified mRNA were used for vaccine delivery this potential benefit might be
compromised. This drawback might be mitigated through careful selection of the
nucleoside modification used. For example, incorporation of m5C in mRNA enhances
translation but m5C-containing mRNA still activates primary DC. Alternatively, a
vaccine based on modified mRNA may need to be supplemented with an adjuvant. This
would enhance immunostimulation, while still retaining the other advantageous
properties of nucleoside-modified mRNA. In addition, the lack of PKR and OAS
activation in the DC would allow greater production of important cytokines and
costimulatory molecules needed in the generation of an effective adaptive immune
response.
For ex vivo delivery of mRNA, nucleofection is an efficient delivery approach but,
as we demonstrate, also induces phosphorylation of eIF2α. Phosphorylation of eIF2α
concurrent with mRNA delivery will limit translation during the critical window when
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the concentration of transfected mRNA is at its peak. Strategies to circumvent this caveat
are needed to maximize the utility of this transfection method.
Translation of both unmodified and Ψ-containing mRNA was increased in PKR−/−
MEF cells compared to WT cells. This result is intriguing, but extrapolation of data
obtained through direct comparison must be taken with caution given the clonal nature of
the cells used in this study. However, if this result is repeatable in primary cells from
PKR−/− mice, it suggests that further translational enhancement of modified RNA can be
obtained in the absence of PKR activity. Co-delivery of PKR inhibitors or siRNA with
therapeutic mRNA could permit additional translational enhancement.
Importantly, the modifications tested herein all occur naturally in cells and do not
run the potential risks associated with chemically synthesized modified nucleosides that
do not occur naturally in RNA. Of the modifications tested, U-modifications most
consistently reduced RNA sensor activation and Ψ-modification produced the largest
increase in translation. Therefore, we propose that of the tested modifications, Ψcontaining mRNA has the largest potential therapeutic benefit. Studies of additional U
modifications may yet identify additional modified mRNAs with even better properties
offering still greater therapeutic benefits.

5.5 Future directions and applications
Although RNase L cleaves unmodified RNA more efficiently than Ψ-containing
mRNA in vitro, the half-life of Ψ-modified mRNA is longer than that of unmodified
mRNA in both WT and RNase L−/− MEF. Therefore, the factor(s) responsible for the
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enhanced retention of Ψ-mRNA remain unknown at this time. The enhanced persistence
of Ψ-mRNA may result from reduced nuclease cleavage at Ψ residues. Nucleases that
could be responsible for the enhanced stability of Ψ-mRNA include Xrn1 or the exosome,
which comprise the predominant RNA degradation pathways 16, or ISG20, an IFNinducible ssRNA-specific ribonuclease 183. A related possibility is that the presence of Ψ
alters RNA binding by non-RNase proteins which facilitate RNase activity, such as zincfinger antiviral protein (ZAP) or exosome components 98. Alternatively, the presence of
Ψ has also been shown to increase the thermal stability of RNA duplexes, and in this way
could reduce RNA accessibility to ssRNA-specific nucleases.
Additional experiments are needed to expand our understanding of nucleofectioninduced eIF2α phosphorylation. In GCN2−/− MEF the timing of eIF2α phosphorylation
was delayed and the extent was reduced. This indicates that GCN2 contributes to
nucleofection-induced phosphorylation but may not be solely responsible. An initial
study in GCN2−/−/PERK−/− double-knockout cells suggested that nucleofection does not
induce eIF2α phosphorylation if both PERK and GCN2 are absent. Examining GCN2
and PERK phosphorylation in WT and GCN2−/− cells will verify GCN2 and PERK
activation following nucleofection. In addition, although inhibition of translation is the
expected result of eIF2α phosphorylation, this should be experimentally confirmed and
its effect on translation of transfected mRNA should be demonstrated. Finally, the extent
and duration of nucleofection-induced eIF2α phosphorylation should be examined in
clinically relevant cells such as human T-cells.
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The effect of modified nucleosides on other RNA sensors needs to be investigated,
including NLRs, ADAR, and HMGBs. We propose that nucleoside modifications will
reduce activation of these sensors. In addition to PKR, other unidentified proteins were
pulled down from cell lysates by unmodified mRNA by not by Ψ-mRNA, and we
hypothesize that some of these proteins may yet be identified as other RNA sensors. It
will also be of interest to identify the protein that was pulled down specifically by ΨmRNA.
The conceptual value of modified mRNA must also be tested in translational
therapeutic models. Delivery of mRNA containing modified nucleosides could readily be
tested for treatment of conditions that are currently treated by injection of purified
proteins, such as erythropoietin for treatment of anemia, clotting factors VIII and IV for
hemophilia, and IFN for cancer and anti-viral therapies. Abundant clinical and preclinical trials are investigating the mRNA transfection of DCs for anti-tumor
immunotherapy, and these as well as other vaccination strategies could benefit from the
use of modified mRNA. The ability to generate iPS cells through transfection of a limited
number of transcription factors holds great promise for the development of cell therapies.
However, the clinical application of iPS cells may be limited by the risks associated with
integration of the retroviral vectors used for transduction. Therefore, delivery of
transcription factors encoded on modified mRNA may provide a safer alternative method
for iPS cell generation.
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A.1 Abstract
The development of an HIV vaccine that induces broad and potent immunity is
critically needed. Viruses, including lentiviruses, have been used as vectors for ex vivo
transduction of antigens into dendritic cells (DC). We hypothesized that DC transduced
with a vector that allows selective infection of DC could induce potent immunity by
continually priming DC. A lentiviral vector encoding HIV gag-pol without env would
form viral cores in transduced DC, but would release non-infectious particles by budding
into endosomes and releasing apoptotic bodies or exosomes containing viral cores. DC
function by endocytosing DC-derived apoptotic bodies, and they are specialized in their
ability to move endocytic contents into the cytoplasm. We postulated that endocytosis of
vector cores could lead to transduction of a second round of DC. In this report, we
demonstrate accumulation of viral cores inside transduced DC and show second-round
transduction of immature DC that endocytose transduced DC in vitro. The effectiveness
of immunization of mice with transduced DC to induce specific lymphocyte activation
was assessed. Mice developed antigen-specific T cell responses and specific antibodies
after immunization. Transduction of DC with a replication-competent but conditionally
infectious lentivirus could be a novel vaccine strategy for HIV.
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A.2 Introduction
A safe and effective vaccine for HIV is critically needed to combat the worldwide
scourge of AIDS. While the correlates of immune protection have yet to be clearly
defined, either for protective or therapeutic vaccines, it is widely believed that both CD4+
and CD8+ T cell as well as humoral immunity are important. How sufficiently broad,
potent, and sustained responses can be elicited has yet to be determined, and this
represents a critical gap in our understanding of how to generate an effective vaccine
such that protective or therapeutic immunity can be achieved.
Selection and activation of lymphocytes is a function of antigen presentation by
dendritic cells (DC), making DC a logical vehicle for immunotherapy 11. Early studies
showed that DC loaded with tumor extracts 6, 182 or antigenic peptides 6, 41, 164, 182 induced
anti-tumor immunity in both laboratory mice 6, 41, 164 and human melanoma patients 182.
More recently, viruses have been used as gene transfer vectors for the ex vivo
transduction of DC with selected antigens. Lentiviral vectors have a number of
advantages over adenoviruses, adeno-associated viruses, poxviruses, and alphaviruses.
Transduction is stable due to chromosomal integration and non-dividing cells are
efficiently transduced 153. Lentivirally transduced DC have been studied for their ability
to induce anti-tumor immunity. Breckpot et al. 31 demonstrated that murine DC
transduced with a lentivirus encoding a truncated variant of ovalbumin (OVA) protected
against tumor challenge with OVA-expressing cells. He et al. 110 recently described the
transduction of murine DC with a lentiviral vector encoding OVA, and showed, by direct
comparison, superiority to peptide/protein-pulsed DC for the stimulation of T cell
responses. B cell responses to lentiviral vector-transduced DC are typically absent.
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Optimal antigen presentation depends on the form in which the antigen is
delivered as well as DC activation (reviewed in 12), which is induced in vivo by the
interaction of pathogen-associated molecular patterns with Toll-like receptors (TLR) on
DC, as well as other inflammatory mediators and receptors. Most DC vaccination
strategies employ ex vivo maturation through one of several agents, such as TLR4recognized lipopolysaccharide 31, 275 or tumor necrosis factor-α (TNF-α) 165. Mature DC,
after activating T cells, undergo apoptosis 58. Therefore, regardless of the stability of DC
transduction, optimal antigen presentation is limited to the time during which the
transduced DC are mature but non-apoptotic. The added complication to induction of
immunity against transformed cells and possibly also chronic viral infections is that in the
absence of a continued danger signal, the immune response may diminish. This has led to
the hypothesis that repeated immunization with cancer vaccines are required 32. The weak
immunogenicity of many important antigens led us to consider whether we could
overcome the apoptosis limitation and develop an approach that continues to prime until
a strong antigen-specific effector response is achieved.
Lentiviruses have three main genes: gag, pol, and env. The gag and pol genes
encode proteins required to replicate nucleic acid and assemble and process the virus, but
env is required for infectivity. It has been demonstrated that a vector containing gag and
pol but not env makes and releases viral cores 83, 94, but these cores are not infectious. In
lymphoid organs, mature DC apoptose after presenting their antigens to T and B cells.
The resulting apoptotic bodies are taken up by neighboring DC leading to a process of
antigen sharing 2. DC are highly specialized in moving endocytic contents into their
cytoplasm 61, 86, 158, 163, 190, 227, and we hypothesized that uptake of free viral cores or
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apoptotic bodies or exosomes containing viral cores could lead to transduction of the
engulfing DC. As this would lead to continued priming through multiple cycles of
engulfment, vaccination with DC transduced with such a vector would induce strong,
specific T and B cell responses against vector constituents.
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A.3 Materials and methods
Mice
Female BALB/c mice aged 6 weeks were purchased from Charles River
Laboratories (Wilmington, MA) and cared for according to institutional guidelines at the
University of Pennsylvania under a protocol approved by the Institutional Animal Care
and Use Committee.

DC generation
Murine DC were generated as previously described 122, 154 in RPMI 1640
(Invitrogen, Carlsbad, CA) containing 10% heat-inactivated fetal bovine serum (FBS;
HyClone Laboratories, Logan, UT), 2 mM L-glutamine, 10 mM HEPES buffer solution
(RPMI/10% FBS; Invitrogen) and 20 ng/mL recombinant mouse GM-CSF (R&D
Systems, Minneapolis, MN). Media with GM-CSF were replaced every 2–3 days and DC
were harvested on day 7.

Lentiviral vector production and determination of copy number
Vectors were created by VIRxSYS Corporation. Their genomic structure and
production has been previously described 152. Briefly, a two-plasmid system packages
vector genome, as well as reverse transcriptase and integrase. Viruses were pseudo-typed
with vesicular stomatitis virus-G envelope, and copy number was determined by TaqMan
quantitative PCR. Vector VRX418 encodes full-length, functional gag-pol, while the
otherwise identical control vector, VRX494, does not. Both vectors express eGFP.
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Transduction of DC with lentiviral vector
Concentrated vector solution (~109 transducing units/mL) was added to DC at a
MOI of 50 and incubated overnight. Cells were extensively washed, TNF-α (16 ng/mL;
R&D Systems) was added, and cells were incubated overnight. Negative control DC were
treated identically except for vector addition. In certain experiments, spinoculation was
used (2 hours at 1200 × g), where a non-significant increase in transduction efficiency
was noted 189.
Second-round transduction was performed by freeze-thawing 1–2 × 105
transduced, with either VRX418 or VRX494 (range of transduction efficiencies from 25
to 55%), DC three times using dry ice and a 37º C water bath and adding them to tenfold
more (based on the number of transduced cells) autologous DC. The second set of DC
were prepared 1 week after the first set. One and 4 days after addition of freeze-thawed
DC to new DC, cells were analyzed by flow cytometry.

Real-time PCR
Cells (2.5 × 103) were lysed (100 mM KCl, 0.1% Nonidet P-40, 20 mM Tris pH
8.0, 500 µg/mL proteinase K (Sigma-Aldrich, St. Louis, MO) at 60º C overnight, then at
90º C for 25 minutes. Real-time PCR was performed in an Applied Biosystems Prism
7700 Sequence Detector (Foster City, CA) using AmpliTaq Gold enzyme with buffer II
per manufacturer's instructions (Applied Biosystems), including 50 mM MgCl2 and 2.5
mM of each dNTP (Promega, Madison, WI). Gag DNA was detected using the following
primers and probe: 5’-CAGAATGGGATAGATTGCATCCA-3’, 5’ATCCTATTTGTTCCTGAAGGGTACTAGTA-3’, and 5’-[FAM]104

CTATTGCACCAGGCCAGATGAGAGAACC-[TAMRA]-3’ (Sigma-Genosys, The
Woodlands, TX). Copy number was quantified against a dilution series from lysed ACH2 cells (NIH AIDS Research and Reference Reagent Program; original source Dr. T.
Folks 47, 85). Quantification of the abortive forms, 2-LTR circles 33, used the following
primers and probe: 5’-GCTAACTAGGGAACCCACTGCTTA-3’, 5’TCAGGGAAGTAGCCTTGTGT3’, and 5’-[FAM]-GTCACACAACAGACGGGCACACACTACT-[TAMRA]-3’.

p24 ELISA on DC culture supernatants
Transduced DC supernatants were analyzed for p24 gag protein content by
ELISA (Beckman Coulter, Fullerton, CA).

Electron microscopy with anti-p55 staining
DC were analyzed according to standard EM protocols by the University of
Pennsylvania Biomedical Imaging Core and stained using a monoclonal antibody to HIV1 p55 (ARP313; Centralized Facility for AIDS Reagents, Herts, UK; original source Drs.
R. B. Ferns and R. S. Tedder 80, 81 . ARP313 was visualized using anti-mouse IgG labeled
with electron-dense gold particles 181.

Vaccination and serum collection
Mature DC were resuspended in PBS at 5 × 106 cells/mL. Mice were injected
with 1 × 105 VRX418-transduced DC in a hind footpad. Control mice were injected with
1 × 105 untransduced, matured DC. Immunizations were separated by 2 weeks for two to
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three injections. Animals were sacrificed 7–12 days after the final injection, with all
animals in a given group analyzed simultaneously. Prior to injections, serum was
collected from each mouse using a Goldenrod Animal Lancet (MEDIpoint, Mineola, NY).

Flow cytometry
Transduced DC expressing eGFP were analyzed with the addition of propidium
iodide (PI) to exclude dead cells. For intracellular p24 analyses, DC were fixed in 2%
paraformaldehyde (Sigma-Aldrich), which quenches eGFP, and permeabilized in
PBS/1% FBS/0.1% saponin (Sigma-Aldrich). Samples were stained with anti-p24-FITC
antibody (KC57) (Beckman Coulter) for 30 minutes at room temperature, washed, and
analyzed. Samples for the above experiments were acquired on FACScan and
FACSCalibur flow cytometers (BD Biosciences, San Jose, CA), and data were analyzed
using FlowJo software (Tree Star, Ashland, OR).
For Tetramer analyses, splenocytes were incubated with Fc block (anti-mouse
CD16/CD32; BD Pharmingen), and then stained with MHC class I tetramer H2Kd/AMQMLKETI-streptavidin-PE (NIAID MHC Tetramer Facility, Atlanta, GA;
peptide from New England Peptide, Gardner, MA) 161. Samples were then stained with
anti-mouse antibodies CD3e-FITC, CD11b-PerCPCy5.5, and CD8a-PE-Cy7; or CD62LFITC, CD8a-PerCP, and CD11b-allophycocyanin (BD Pharmingen). For certain samples,
prior to running, TO-PRO-3 (Invitrogen) was added.
For intracellular cytokine analyses, splenocytes (5 × 106 cells/mL) were
stimulated with a gag peptide pool (15-mer peptides spanning the protein with 11 amino
acid overlaps, each peptide at 0.25 µg/mL; NIH AIDS Research and Reference Reagent
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Program, No. 8117), or a pool of irrelevant peptides (equally concentrated env clade C
15-mer peptides; NIH AIDS Research and Reference Reagent Program, No. 9499). As a
positive control, splenocytes were treated with 50 ng/mL phorbol 12-myristate 13-acetate
and 500 ng/mL ionomycin calcium salt (Sigma-Aldrich). Human recombinant IL-2 (50
U/µL) was added to enhance IFN-γ production 194. After 1 h, 10 µg/mL brefeldin A
(Sigma-Aldrich) was added. After four more hours, cells were treated with PBS/0.5 mM
EDTA for 10 minutes and then stained with the anti-mouse antibodies CD44-FITC, CD4PerCP, CD8a-PE-Cy7, and CD3eallophycoyanin-Cy7 (BD Pharmingen), fixed in 2%
paraformaldehyde, permeabilized with 0.1% saponin, and stained for IFN-γ-PE and IL-4allophycocyanin (BD Pharmingen). For tetramer and intracellular cytokine studies, 1 ×
106 events were acquired on a FACSCanto (BD Biosciences) and analyzed using FlowJo
software.

p24 antibody ELISA of serum samples
Serum samples were added in triplicate at 1:50 and 1:500 dilutions to 96-well
plates coated with HIV gag p24 protein (Immunodiagnostics, Woburn, MA). A standard
curve was constructed using a purified anti-HIV-1 p24 monoclonal antibody (183-H12–
5C; NIH AIDS Research and Reference Reagent Program; original source Dr. Bruce
Chesebro and Kathy Wehrly 46, 245). Detection antibody (anti-mouse IgG-peroxidase
antibody; Sigma-Aldrich) was added followed by a 50/50 solution of 3,3’,5,5’tetramethylbenzidine and H2O2 (KPL, Gaithersburg, MD), and absorbance was measured
at 450 nm on a Dynex Technologies MRX microplate reader.
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Statistics
Statistics were performed using Microsoft Excel. Standard errors of the mean
were calculated from triplicate measurements of a sample. Standard deviation and
Students t-test (two-tailed) were used for comparing populations.
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A.4 Results
Lentiviral transduction of murine DC
We first determined the efficiency of transduction of the HIV vector containing
functional gag-pol, VRX418, and the otherwise similar vector VRX494, which lacks a
functional gag-pol (Fig. A-1). During preliminary experiments, we established a protocol
in which bone marrow-derived murine DC were transduced on day 7 at an MOI of 50.
Enhanced GFP (eGFP) expression gave a typical transduction of 20–35% clearly positive
cells after 1 day, which was still present 8 days later (Fig. A-2A and B). These data show
that VRX418 and VRX494 efficiently transduced cultured bone marrow-derived murine
DC. DC were also tested for intracellular p24 content. Fig. A-2C and D show that over
50% of VRX418-transduced cells stained positive after 1 day, which could be argued to
be input virus except that high-level p24 staining remained through 8 days of culture,
while VRX494-transduced DC had baseline p24 staining. The difference in transduction
efficiencies as measured by eGFP and p24 could be explained by the pattern of eGFP
staining where a single shift in expression is observed, but not all cells express enough
eGFP to move beyond the brightest of the unstained population.
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Figure A-1. Map of the VRX418 and VRX494 lentiviral vector genomes
VRX418 and VRX494 are derived from the NL4-3 molecular clone of HIV-1. VRX418
contains 5’- and 3’-LTR, full-length and functional gag and pol, splice donor (SD) and
splice acceptor (SA) sites, an anti-sense envelope payload, the Rev response element
(RRE), and eGFP. VRX494 differs from VRX418 in that the gag-pol gene is replaced
with the genome packaging site (psi) and the central polypurine tract (cPPT).
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Figure A-2. eGFP and p24 gag protein expression in transduced DC
Bone marrow-derived DC were transduced with VRX418 or VRX494 at an MOI of 50.
Flow cytometric analysis was carried out to determine eGFP or intracellular p24 gag
expression. (A) Day-1 plot of eGFP expression in live cells in VRX418- (empty) versus
untransduced (shaded) DC. (B) Continued eGFP expression in VRX418- and VRX494transduced DC through day 8. (C) Day-1 plot of intracellular p24 gag staining in
VRX418-transduced DC (empty) versus untransduced (shaded) DC. (D) Intracellular p24
gag content remained elevated through day 8 post-transduction. Error bars are standard
error of the mean for triplicate measurements. Data are representative of three
experiments.

The high level of intracellular p24 by day 1 shows that gag is produced quickly in
transduced cells, but this does not clarify whether similar levels of continued production
occur. We quantified the amount of p24 in transduced cell culture supernatants over days
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1 through 8. To rule out the possibility that input gag from the vector contributed
significantly to the measured values, we employed the control vector VRX494, which
included a similar amount of input gag, as measured by p24 gag content of viral stocks,
but does not encode functional gag protein. On day 1 post-transduction, cells were
washed three times to remove input virus, and supernatants were collected after 4.5 hours
and then on following days. As shown in Fig. A-3, p24 levels were high (>30 ng/mL) and
remained high over all days of analysis in the VRX418 sample but were baseline in the
VRX494 culture.
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Figure A-3. Extracellular p24 gag production by transduced DC
Bone marrow-derived DC were transduced with VRX418 or VRX494 at an MOI of 50.
Transduced cells were washed three times the following day to remove input virus, and
supernatants were collected on the indicated days. Supernatants were analyzed for p24
gag content by ELISA. The day-6 level of gag protein is likely artificially low as fresh
medium was added to the cells prior to the removal of supernatant for analysis. Error bars
are standard error of the mean for triplicate measurements. Data are representative of
three experiments.

Having proven strong and continued transgene expression, we next sought to
investigate the formation and integration of vector DNA in transduced cells with realtime PCR. The number of gag DNA copies exceeded the number of cells in culture (data
not shown), suggesting either that each cell underwent multiple integrations or that
abortive, non-integrating DNA forms were present. We assayed for 2-LTR circles (and 1LTR circles by implication) 33, and we were able to show their presence, demonstrating
that abortive integrations accounted for a portion of the vector DNA in DC.
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Formation of viral cores in transduced cells
The inclusion of full-length gag-pol within the coding region of the vector would
lead to viral core formation in transduced cells. These would not be expected to form
infectious particles, however, since there is no envelope present, but they could still bud
83, 94

into endosomal compartments and be released (reviewed in 141) or be released within

exosomes (reviewed in 60) or apoptotic bodies. To investigate this phenomenon,
transduced DC were analyzed by electron microscopy (EM) with and without staining for
HIV-1 p55. Illustrative photomicrographs from triplicate sample preparations are shown
(Fig. A-4).
In unstained samples of transduced DC (Fig. A-4A), small round cores (arrows)
demonstrated the formation of vector cores. p55 staining confirmed consistent, significant
p55 presence and clumping within transduced cells (Fig. A-4B) with absence of staining
in untransduced samples (Fig. A-4C). Close grouping of p55 molecules in transduced
samples confirmed viral core formation. The p55 monoclonal antibody specifically stains
immature gag. As an additional control, viral stocks were stained for p55 and fewer than
1% of the viruses had measurable staining. This demonstrated that the viral stock
contained mature virions that did not stain. The identification of stained viral cores within
DC demonstrated that these were newly formed virions and not trapped input virus. One
day after pulsing, a time when exogenously delivered virus is cleared from endosomes 249,
viral cores were observed that had budded into endosomal-like compartments (Fig. A4D). In fact, one of the two virions in the endosome in Fig. A-4D has the morphology of
a matured virion with a well-defined core region. These results correspond closely with
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the antibody staining shown previously 181, and the photomicrographs displayed here
show particles similar to the HIV-1 cores seen in the EM studies of other groups 170, 233.
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Figure A-4. EM of bone marrow-derived DC transduced with VRX418
Cells were transduced at an MOI of 50 and placed in culture for 24 hours. Certain
samples were stained with a monoclonal antibody to HIV-1 p55; the antibody was
visualized using a secondary antibody with attached electron-dense gold particles. (A)
High-power view showing viral cores (arrows) accumulating in the cytoplasm of
transduced DC. (B, C) Gag p55 antibody-stained transduced (B) and untransduced (C)
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DC. Transduced sample (B) shows a clumping distribution of p55 overlying viral cores.
(D) High-power view showing two viral particles in an endosome-like compartment. One
and possibly both of these particles demonstrate the classic appearance of mature
particles with a central core. Scale bars are 100 or 500 nm. Data are representative of
three preparations of transduced DC.

“Second-round” transduction of DC
We next tested whether immature DC could be transduced by uptake of viral
cores from previously transduced cells. This ability would demonstrate that multiple
rounds of transduction are possible, as each generation of DC is transduced by uptake of
viral cores from the previous generation. DC were transduced with either VRX418 or its
non-replicating counterpart, VRX494, and washed extensively to remove unbound virus.
After a 24-hour incubation, cells were washed again, analyzed for eGFP expression, and
equal numbers of transduced DC (5 × 104), set to 1 (Fig. A-5), were freeze-thawed three
times to ensure complete cell death. New, immature DC were then added to each sample
at a 10:1 ratio (5 × 105) to the transduced DC.
eGFP analysis completed 1 and 4 days later showed that added cells in the
VRX418 sample had been transduced as noted by an increase in the number of
transduced cells to 4.5-fold greater than the input number of killed transduced DC, i.e. an
increase from 5 × 104 transduced killed cells to 2.26 × 105 newly transduced added cells
(Fig. A-5). VRX494-transduced cells that were pulsed with equal numbers of infectious
units of vector demonstrated no transduction of second-round DC, indicating that initially
added, trapped vector was not responsible for the second-round transduction.
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Figure A-5. Second-round transduction
Bone marrow-derived DC were transduced with either VRX418 or VRX494. After
overnight incubation and extensive washing, flow cytometric analysis was performed,
and the number of transduced cells in each sample was normalized to allow the addition
of equal numbers of cells that were transduced (set to 1) to tenfold more untransduced
immature DC. The first-round DC were freeze-thawed three times to ensure complete cell
death, and immature second-round DC were then added. After 1 and 4 days, flow
cytometric analysis was performed, which showed increasing transduction in the secondround DC in the VRX418 sample but not in the non-replicating control (VRX494). Data
are representative of three experiments.

T and B cell responses to vaccination
We next sought to test the immunogenicity of vector-transduced DC in a small
animal model. Lentiviral vectors, especially ones based on HIV, that are used in mice
have mammalian promoters to produced tumor-associated antigens 110, 165, 191, 274, 275. The
commonly used Balb/c mouse model should be deficient in the ability of our vector,
which uses HIV's promoter system, to replicate and undergo second-round transduction,
as a post-integration block to HIV replication in mice has been described (reviewed in 50),
although the above data showing p24 gag protein and viral cores suggests that murine DC
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are capable of some level of protein production and virion formation.
Initial experiments looking for subsequent rounds of DC transduction in vivo in
mice found a rapid extinction of vector-derived PCR signal in lymphoid tissue,
suggesting that in the mouse, this vector could not efficiently undergo multiple rounds of
transduction. Thus, repeated immunizations of vector-transduced DC were given to
Balb/c mice. We delivered DC by subcutaneous injection, a route proven to lead to DC
trafficking to draining lymph nodes 205 and induction of immune responses (reviewed in
91, 92

). DC were transduced on day 7 of culture, TNF-α was added on day 8, and 1 × 105

cells, either transduced with VRX418 or untransduced controls, were injected on day 9,
with two or three injections of freshly transduced DC separated by 2 weeks. Following
the final immunization, mice were sacrificed after 7–12 days.
MHC class I tetramer H-2Kd/AMQMLKETI staining demonstrated significant
(p=0.0004) expansion of gag-specific CD8+ T cells. Data for a single experiment (Fig. A6A) and cumulative data for all immunized mice are shown (Fig. A-6B). Splenocyte
populations were assayed for the intracellular production of IFN-γ and IL-4 in response to
stimulation by either a gag peptide pool or a pool of irrelevant peptides. Mice developed
significant CD8 responses as measured by IFN-γ expression (data not shown). CD4
responses were also monitored, and VRX418 DC-immunized mice developed significant
(p=0.00012) CD4+ T cell IFN-γ responses. Data for a single experiment (Fig. A-6C) and
cumulative data for all immunized mice are shown (Fig. A-6D). No mouse developed a
population of IL-4+ CD4+ T cells, arguing that a Th1 response was induced.
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Figure A-6. T cell responses to vaccination with VRX418-transduced DC
Bone marrow-derived DC were transduced with VRX418 at an MOI of 50. (A) TNF-αtreated, transduced (VRX418) or untransduced (control) DC (1 × 105) were injected into
the footpads of mice. Mice were sacrificed 7 days after a boost injection. Splenocytes
were analyzed for tetramer (MHC class I tetramer H-2Kd/AMQMLKETI) expression on
CD8+ T cells. One vector mouse did not receive the second immunization and was
removed from this analysis. (B) Cumulative data for all immunized mice (14 VRX418
and 15 control mice) are shown. Averaged tetramer staining level for each mouse is
shown with standard deviations. (C) Transduced (VRX418) or untransduced (control)
DC were injected into the footpads of mice every 2-weeks for three immunizations. Mice
were sacrificed 11 days after the final injection. Splenocytes were analyzed for antigenspecific IFN-γ production by CD4+ T cells. Data shown are the percentages of CD4+ T
cells that expressed high levels of intracellular IFN-γ. (D) Cumulative data for all
immunized mice are shown. The percent CD4+ T cells expressing IFN-γ were corrected
by subtracting the level of staining from the irrelevant peptide pool averaged. Three
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separate experiments with groups of five mice (represented by individual numbers) were
immunized and analyzed, and representative (A, C) and all (B, D) data are shown.

Serum was collected from each of the animals before each injection (days 0, 14,
and 28) and at sacrifice (days 35–40). A p24-binding antibody ELISA was performed and
the results are shown in Fig. A-7. A purified gag p24-specific monoclonal antibody was
used to generate a standard curve in order to quantify the amount of gag-specific
antibodies in serum. By the third immunization, every mouse immunized with VRX418transduced DC developed high antibody levels (10–120 µg/mL).

121

Figure A-7. Antibody responses to VRX418-transduced DC vaccination
TNF-α treated, VRX418-transduced (squares) or untransduced (triangles) DC (1 × 105)
were injected into the footpads of mice. Two boost injections were performed at 2-week
intervals. Serum was collected before each injection (days 0, 14, and 28) and at sacrifice
(day 39). Serum samples were analyzed in a direct binding ELISA against a standard
curve constructed with an HIV-1 p24 monoclonal antibody. Data are representative of
three experiments. Mean (horizontal bar) and standard deviation (error bars) are shown.
p-values compare VRX418-transduced DC to control DC-immunized mice.
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A.5 Discussion
The purpose of this study was to investigate whether a conditionally infecting
lentivirus could infect a second round of DC by the release of viral cores, either free or as
part of apoptotic bodies or exosomes that are taken up by new DC leading to infection
through the endosomal route. We observed second-round transduction of DC exposed to
killed transduced DC, in vitro. Upon vaccination with these transduced DC, we observed
potent anti-gag T and B cell activation. Unlike most studies that have induced T cell
responses against diverse antigens through a variety of lentiviral approaches 78, 110, 165, 191,
274

, the potent B cell response is novel.
While we were able to demonstrate second-round infection of DC in vitro, we

could not demonstrate this in vivo and needed to reimmunize mice to obtain potent
responses. This is likely due to the post-integration block to HIV replication in mice 50
that makes second-round transduction an inefficient process. The likely mechanism for
the potent CD4, CD8, and B cell response observed with VRX418 was the continuous
production of gag-pol protein that was released as free protein or viral-like particles. The
role of second-round infection/transduction in immune response development, in vivo,
could not be measured, but remains the focus of future studies.
VRX418 efficiently transduced bone marrow-derived murine DC, as evidenced
by eGFP expression (Fig. A-2A and B), intracellular and extracellular p24 gag protein
(Fig. A-2C, D and A-3), and the presence of gag DNA in transduced cells (data not
shown). EM studies demonstrated approximately 100-nm viral cores in the cytoplasm and
endosomes and a clumping distribution of anti-p55 antibody in association with cores
within the cytoplasm of transduced cells (Fig. A-4). We hypothesized that these viral
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cores would become accessible to immature DC for uptake by phagocytosis of apoptotic
vesicles or exosomes. In addition, we observed mature virions in endocytic vesicles (Fig.
A-4D) that could be released from transduced DC. Uptake by immature DC would then
make possible a “second round” of transduction if vector cores could escape from the
endosome to transduce the engulfing cell. This has been demonstrated to be a pathway
for HIV infection in multiple cell types 54, 82, 105, 113, 193, 257.
Figure A-8 illustrates this hypothesis in the context of our experiments. We
designed in vitro investigations where we killed transduced cells that contained no
original infectious vector and then added fresh, immature DC. When we analyzed these
added DC by flow cytometry 1 and 4 days later, we found an increasing level of eGFP
expression (Fig. A-5), indicating that these newly added, immature cells had been
transduced by the viral cores present in the apoptotic DC. To exclude the possibility that
the new DC were actually infected by free infectious virions from the initial transduction,
we (i) waited a length of time shown in other studies to degrade endocytosed virus in DC
and (ii) used DC infected with the same MOI of VRX494, a vector incapable of
replication, and observed no increase in eGFP expression in exposed DC (Fig. A-5). This
demonstrates that our “second-round” hypothesis occurs in vitro.
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Figure A-8. Illustration of mechanism for second-round transduction
Viral cores formed in the cytoplasm of DC transduced with the self-replicating,
conditionally infectious lentivirus VRX418 are released by budding into endocytic
vesicles followed by fusing of the vesicles with the plasma membrane, release of
apoptotic bodies containing viral cores (pictured), and release of exosomes with viral
cores. The viral cores are accessible to immature DC by endocytosis. Viral cores gain
entrance to the DC cytoplasm and begin a second round of transduction. The cycle
continues, with each round of transduced DC presenting antigen to T and B cells and
activating specific immunity against the vector-derived antigens. The continued
presentation would only end when cell-mediated immunity was able to eliminate
transduced DC. Thus priming continues until a potent response develops.

When mice were immunized with transduced DC, we observed no significant
evidence of second-round transduction in limited experimentation, and we had to
reimmunize mice to generate a potent response. It is understood that virions need to bud
before efficient maturation occurs, and this would be required for second-round
transduction. We believe that apoptotic blebbing of viral cores, or endocytic release of
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viral cores as was observed by EM, led to virion maturation, but second-round
transduction was a relatively inefficient process in vitro and likely a more inefficient
process in vivo in the mouse model system where a post-integration block to viral
replication has been observed 50. Our in vitro studies demonstrate that vector/viral
replication in murine cells is not completely blocked. This is supported by other studies
(reviewed in 65). It has been observed that by simply codon optimizing viral sequences,
the production of infectious virions from murine cell lines could occur 65. Further studies
are needed to optimize second-round transduction in vivo in models where HIV- or SIVbased vectors replicate efficiently.
Although antigen transfer in lymph nodes has been studied 17, 37, the mechanism
in our system differs from the native activity of circulating and resident DC in that
replication-competent viral cores are the antigen transfer vehicle. Studies of crosspresentation have demonstrated that breakdown of endosomes and release of their
contents occurs 61, 86, 158, 163, 190, 227, especially after certain types of DC activation
including those induced by TLR3 and TLR9 ligands 55, 224. Proteins made within a cell
are processed and presented via the MHC class I pathway, whereas exogenous proteins
are presented by MHC class II. Although DC cross-presentation of exogenously obtained
peptides by MHC class I is often discussed 59, 89, MHC class II presentation of
endogenous antigens is a more novel concept. Typically, antigens produced within a DC
to which a CD4 response is desired are linked to an endosomal protein such as lysosomeassociated membrane protein 1 175. A likely explanation for the strong CD4 response in
our study is that DC secreted and then endocytosed gag protein or whole viral cores, thus
enabling processing via the MHC class II pathway. Our laboratory has previously
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demonstrated this phenomenon after gag mRNA transfection of PBMC-derived human
DC 262. The potent antibody response directed against gag was likely induced by a similar
mechanism of release of gag protein or whole virions and activation of B cells.
Our work may be initially applicable as an HIV vaccine strategy, although future
uses could include immunization against a variety of transgene-encoded antigens. The
antibody responses to gag are not useful against HIV and do not constitute a viable
vaccine strategy. However, given the strong and broad immune responses that the mice
developed, a reasonable strategy could be modifying the vector to encode a defective env
that induces neutralizing antibodies, or even to use a membrane-based protein that
contains neutralizing antibody-inducing epitopes 62, 87, 119, 137, 284. Such a strategy could
generate potent T cell immunity against gag-pol and potentially env as well as a
neutralizing antibody response to envelope.
We observed potent CD4+ and CD8+ T cell and antibody responses. In a direct
comparison of vaccines, a Listeria monocytogenes recombinant vaccine expressing HIVgag 162 arm was included in our studies. We observed that there was a similar gagspecific tetramer and CD4+, IFN-γ+ response comparing Listeria to our lentiviral
approach (data not shown). No antibody response was observed with the Listeria-gag
vaccine. The response induced by a vaccine is dependent on its mode of delivery of
antigen to the APC. Adjuvanted protein typically induces CD4+ T cell and antibody
responses but is deficient in CD8+ T cell responses because no cytosolic protein
production occurs (reviewed in 147). Attenuated viruses with limited ability to replicate in
cells induce CD4+ and CD8+ T cell and antibody responses are typically used as boosters
to other priming vaccines (protein and DNA). The amount of gag-specific antibody in our
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study appears typical of the level observed in these studies (reviewed in 147).
An interesting facet of this work is the efficiency with which the transduced DC
produced gag protein (Fig. A-2C, D and A-3) in the absence of Rev and Tat. The vector
is designed such that a 5’-splice donor site exists between the 5’-LTR and the gag
sequence, and a 3’-splice acceptor site is present downstream of the Rev response
element and 5’ to eGFP. The presence of Rev and Tat enable production of full-length
genomes, a fact that is employed during production of the vector for clinical use 152. In
the absence of Rev and Tat, however, minimal promoter activity and splicing of any
transcripts produced should occur, yielding predominantly eGFP mRNA. Our results,
however, indicate that murine DC are able to bypass these mechanisms and express large
quantities of gag in a Rev- and Tat-independent manner, although an explanation for this
phenomenon is not readily apparent. It is possible that transcription occurs due to the
high levels of NF-κB members in DC (reviewed in 10), which are augmented by TNF-α
activation. Nonetheless, the extremely high level of gag production in the absence of Rev
remains surprising.
Our lentiviral construct contains the necessary components to form viral cores but
cannot produce infectious virus since no envelope is present. Insertional mutagenesis is a
chief concern with any lentiviral approach, as recent adverse events from retroviral
therapy have made clear 99. This concern is lessened, however, when lentiviruses are used
to transduce only terminally differentiated cells, as in this ex vivo DC system. The
specific vector employed, VRX418, has been constructed by VIRxSYS Corporation
(Gaithersburg, MD) in a manner analogous to the first lentiviral vector approved for use
in a clinical trial, VRX496 118, 152, 159. Production safety mechanisms are therefore already
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in place to allow promising vectors to enter clinical trials expeditiously, and issues
pertaining to scaled manufacturing have been addressed 152. Additional safety and
production issues for lentiviral vector work have been recently reviewed 230.
Antigen-specific immune responses form the basis of host defense against most
infectious and neoplastic processes. The development of an effective vaccine against HIV
that either alters the course of infection or induces sterilizing immunity is critically
needed. We have demonstrated strong and broad immune responses in mice vaccinated
with DC transduced with the replicating conditionally infectious lentiviral vector
VRX418. This study identifies two future directions: (i) to study in a more appropriate
model and improve the in vivo second-round transduction that will allow a single
injection of transduced DC to induce a potent and broad immune response, and (ii) to
understand and develop the current vector to induce antibodies with neutralizing activity
against HIV.
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